

平成 30 年度 医学教育部分分野別研究・教育課題一覧

※「しおり」機能で、目次よび各分野のページにジャンプします
(青字以外の分野はデータなし)

【臨床(外科)系】

- [1. 消化器外科学 Gastroenterological Surgery](#)
- [2. 呼吸器外科学 Thoracic Surgery](#)
- [3. 心臓血管外科学 Cardiovascular Surgery](#)
- [4. 乳腺内分泌外科学 Breast and Endocrine Surgery](#)
5. 小児外科学移植外科学 Pediatric Surgery and Transplantation
- [6. 脳神経外科学 Neurosurgery](#)
- [7. 整形外科学 Orthopaedic](#)
8. 産科婦人科学 Obstetrics and Gynecology
- [9. 泌尿器科学 Urology](#)
- [1 0. 眼科学 Ophthalmology](#)
- 1 1. 耳鼻咽喉科頭頸部外科学 Otolaryngology-Head and Neck Surgery
- [1 2. 歯科口腔外科学 Oral and Maxillofacial Surgery](#)
- [1 3. 皮膚病態治療再建学 Dermatology and Plastic Surgery](#)
- [1 4. 麻酔科学 Anesthesiology](#)
- [1 5. 臨床国際協力学 International Medical Cooperation](#)

※国立病院機構熊本医療センターとの連携講座

消化器外科学分野

【研究プロジェクト名および概要】

I. 消化管領域における研究

- ・ GIST における Imatinib 耐性獲得機構の解明
- ・ 消化管癌に関与する癌代謝関連遺伝子の解明
- ・ 消化管癌と内臓脂肪、サルコペニアの関連
- ・ 癌幹細胞性維持に関わる機能の解明
- ・ 癌をとりまく微小環境の解明
- ・ 消化管癌化学療法効果予測因子の探索と臨床応用
- ・ 胃癌腹膜播腫の予防的治療戦略の確立
- ・ 胃癌における癌関連線維芽細胞 (CAF) と癌細胞との相互作用と癌進展の機序解明
- ・ 大腸癌におけるオルガノイドを用いた癌進展に寄与する関連遺伝子の解析

II. 肝・胆膵領域における研究

- ・ がん幹細胞マーカーが膵癌進展を引き起こすメカニズムの解明
- ・ 肝胆膵領域癌における腫瘍関連間質細胞の解析
- ・ 肝星細胞の癌相互作用による浸潤・転移機構の解明
- ・ 新規画像診断技術による機能的肝体積に基づいた肝切除適応基準の確立
- ・ 膵癌 CAF における細胞老化の意義と臨床応用
- ・ 肝胆膵領域癌におけるサルコペニアの臨床的意義
- ・ ex vivo 培養系を用いた薬物治療標的の探索
- ・ ミニチュアヒト肝臓を用いた肝細胞癌の浸潤転移機序の解明
- ・ 肝内胆管癌原発巣と転移巣の遺伝子発現の網羅的解析
- ・ 生体吸収性人工胆管の開発

III. 外科一般 に関する研究

- ・ 消化器癌の発育・進展に関与する癌関連遺伝子の解明
- ・ microRNA をターゲットとした消化器癌に対する新たな治療戦略の開発
- ・ 消化器癌におけるエピゲノム変化の網羅的解析
- ・ 消化器癌における免疫チェックポイント機構の解明
- ・ 消化器癌における腸内細菌叢の解析
- ・ がん代謝が消化器癌に及ぼす生理学的意義の解明

【教職員・医員および大学院生】

教授	馬場 秀夫
准教授	石河 隆敏
准教授	近本 亮
特任准教授	吉田 直也
准教授	山下 洋市
講師	宮本 裕士
特任講師	馬場 祥史
特任助教	岩上 志朗
助教	林 洋光
特任准教授	石本 崇胤
助教	岩槻 政晃
助教	今井 克憲
助教	日吉 幸晴
助教	岡部 弘尚
救急・総合診療部 助教	辛島 龍一
特任助教	中川 茂樹
医員	
大学院生 (4 年生)	
大学院生 (3 年生)	
大学院生 (2 年生)	
大学院生 (1 年生・社会人大学院生)	

【メールアドレス】

hdobaba@kumamoto-u.ac.jp
ishiko@kumamoto-u.ac.jp
chika@kumamoto-u.ac.jp
nyoshida@kumamoto-u.ac.jp
y-yama@kumamoto-u.ac.jp
miyamotoyuji@kumamoto-u.ac.jp
y-baba@kumamoto-u.ac.jp
s-iwagami@kumamoto-u.ac.jp
hhayasi@kumamoto-u.ac.jp
taka1516@kumamoto-u.ac.jp
maiwa217@kumamoto-u.ac.jp
katsuimai@hotmail.com
yukiharu@kumamoto-u.ac.jp
okabeh@kumamoto-u.ac.jp
karagon@kumamoto-u.ac.jp
shigekn2@kumamoto-u.ac.jp

【研究プロジェクト】

I II III (研究の統括)	
I	II III
II	III
II	III
I	III
II	III
I	III
I	III
II	III
I	II III
I	III
II	III
I	III
II	III

長井 洋平、江藤 弘二郎
宮田 辰徳、清住 雄希、古閑 悠輝、八木 泰佑、梅崎 直紀、
内原 智幸、山尾 宣暢、織田 枝里
伊東山 瑠美、岡留 一雄、坂本 悠樹、大徳 暢哉、中尾 陽佑、
山下 晃平、遊佐 俊彦、Rebecca Kalikawe
秋山 貴彦、上村 紀雄、北村 文優、野元 大地、夏 跃超、
布鲁克
松村 和季、山根 大侍、森永 剛司、付 凌峰、胡 熙晨

【連絡先】 電話: 096-373-5211 Fax: 096-371-4378

【ホームページ】 <http://www2.kuh.kumamoto-u.ac.jp/shoukakeika/>

【特殊技術】

1. Pyrosequencing 法を用いた遺伝子解析
2. 腹膜播腫に対する遺伝子治療
3. 食道・胃・大腸癌に対する完全鏡視下手術
4. 腹腔鏡(補助)下 肝・膵切除

【英文論文】

1. Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, Shi Y, da Silva A, Gu M, Li W, Keum N, Zhang X, Wu K, Meyerhardt JA, Giovannucci EL, Giannakis M, Rodig SJ, Freeman GJ, Nevo D, Wang M, Chan AT, Fuchs CS, Nishihara R, Ogino S: Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. *J Clin Oncol* 35(16):1836-1844, 2017.
2. Liu L, Nishihara R, Qian ZR, Tabung FK, Nevo D, Zhang X, Song M, Cao Y, Mima K, Masugi Y, Shi Y, da Silva A, Twombly T, Gu M, Li W, Hamada T, Kosumi K, Inamura K, Nowak JA, Drew DA, Lochhead P, Noshok K, Wu K, Wang M, Garrett WS, Chan AT, Fuchs CS, Giovannucci EL, Ogino S: Association Between Inflammatory Diet Pattern and Risk of Colorectal Carcinoma Subtypes Classified by Immune Responses to Tumor. *Gastroenterology* 153(6):1517-1530 e14, 2017.
3. Ishimoto T, Miyake K, Nandi T, Yashiro M, Onishi N, Huang KK, Lin SJ, Kalpana R, Tay ST, Suzuki Y, Cho BC, Kuroda D, Arima K, Izumi D, Iwatsuki M, Baba Y, Oki E, Watanabe M, Saya H, Hirakawa K, Baba H, Tan P: Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells. *Gastroenterology* 153(1):191-204 e16, 2017.
4. Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, Liao X, Noshok K, Chan AT, Giannakis M, Bass AJ, Hodi FS, Freeman GJ, Rodig S, Fuchs CS, Qian ZR, Ogino S: Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. *Gut* 66(8):1463-1473, 2017.
5. Mehta RS, Nishihara R, Cao Y, Song M, Mima K, Qian ZR, Nowak JA, Kosumi K, Hamada T, Masugi Y, Bullman S, Drew DA, Kostic AD, Fung TT, Garrett WS, Huttenhower C, Wu K, Meyerhardt JA, Zhang X, Willett WC, Giovannucci EL, Fuchs CS, Chan AT, Ogino S: Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue. *JAMA Oncol* 3(7):921-927, 2017.
6. Piao X, Yamazaki S, Komazawa-Sakon S, Miyake S, Nakabayashi O, Kurosawa T, Mikami T, Tanaka M, Van Rooijen N, Ohmuraya M, Oikawa A, Kojima Y, Kakuta S, Uchiyama Y, Tanaka M, Nakano H: Depletion of myeloid cells exacerbates hepatitis and induces an aberrant increase in histone H3 in mouse serum. *Hepatology* 65(1):237-52, 2017.
7. Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C: S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial. *Ann Oncol* (Doi: 10.1093/annonc/mdx816), 2017.
8. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Jr., Barzi A, Yamaguchi T, Loupakis F, Lenz HJ: Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. *Ann Oncol* 28(5):1015-1022, 2017.
9. Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W, Falcone A, Loupakis F, Lenz HJ: Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. *Ann Oncol* 28(11):2780-2785, 2017.
10. Higashi T, Friedman SL, Hoshida Y: Hepatic stellate cells as key target in liver fibrosis. *Adv Drug Deliv Rev* 121:27-42, 2017.
11. Yagi T, Baba Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Baba H: PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. *Ann Surg* (Doi: 10.1097/SLA.0000000000002616), 2017.
12. Nakashima Y, Saeki H, Nakanishi R, Sugiyama M, Kurashige J, Oki E, Maehara Y: Assessment of Sarcopenia as a Predictor of Poor Outcomes After Esophagectomy in Elderly Patients With Esophageal Cancer. *Ann Surg* (Doi: 10.1097/SLA.0000000000002252), 2017.
13. Imai K, Benitez CC, Allard MA, Vibert E, Cunha AS, Cherqui D, Castaing D, Bismuth H, Baba H, Adam R: Impact of Surgical Treatment for Recurrence After 2-Stage Hepatectomy for Colorectal Liver Metastases, on Patient Outcome. *Ann Surg* (Doi: 10.1097/SLA.0000000000002472), 2017.
14. Horikawa I, Park KY, Isogaya K, Hiyoshi Y, Li H, Anami K, Robles AI, Mondal AM, Fujita K, Serrano M, Harris CC: Delta133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells. *Cell Death Differ* 24(6):1017-1028, 2017.
15. Torzilli G, Adam R, Vigano L, Imai K, Goransky J, Fontana A, Toso C, Majno P, de Santibanes E: Surgery of Colorectal Liver Metastases: Pushing the Limits. *Liver Cancer* 6(1):80-89, 2017.
16. Kosumi K, Masugi Y, Yang J, Qian ZR, Kim SA, Li W, Shi Y, da Silva A, Hamada T, Liu L, Gu M, Twombly TS, Cao Y, Barbie DA, Noshok K, Baba H, Garrett WS, Meyerhardt JA, Giovannucci EL, Chan AT, Fuchs CS, Ogino S, Nishihara R: Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. *Onc Immunology* 6(3):e1284720, 2017.
17. Hanyuda A, Cao Y, Hamada T, Nowak JA, Qian ZR, Masugi Y, da Silva A, Liu L, Kosumi K, Soong TR, Jhun I, Wu K, Zhang X, Song M, Meyerhardt JA, Chan AT, Fuchs CS, Giovannucci EL, Ogino S, Nishihara R: Body mass index and risk of colorectal carcinoma subtypes classified by tumor differentiation status. *Eur J Epidemiol* 32(5):393-407, 2017.
18. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ: Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. *Int J Cancer* 141(2):383-392, 2017.
19. Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ: Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. *Int J Cancer* 141(6):1222-1230, 2017.
20. Keum N, Yuan C, Nishihara R, Zoltick E, Hamada T, Martinez Fernandez A, Zhang X, Hanyuda A, Liu L, Kosumi K, Nowak JA, Jhun I, Soong TR, Morikawa T, Tabung FK, Qian ZR, Fuchs CS, Meyerhardt JA, Chan AT, Ng K, Ogino S, Giovannucci EL, Wu K: Dietary glyceemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. *Int J Cancer* 140(12):2648-2656, 2017.
21. Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Yamashita Y, Yoshida N, Chikamoto A, Baba H: The microbiome and hepatobiliary-pancreatic cancers. *Cancer Lett* 402(2017):9-15, 2017.
22. Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA: Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. *Br J Cancer* 117(5):648-655, 2017.

23. Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqbal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ: Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. *Cancer* 123(22):4506-4514, 2017.
24. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Jr., Barzi A, Yamaguchi T, Loupakis F, Lenz HJ: Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. *Eur J Cancer* 86:197-206, 2017.
25. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ: Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. *Eur J Cancer* 77:13-20, 2017.
26. Maeda K, Takaki M, Akagi J: Decreased Skeletal Muscle Mass and Risk Factors of Sarcopenic Dysphagia: A Prospective Observational Cohort Study. *J Gerontol A Biol Sci Med Sci* 72(9):1290-1294, 2017.
27. Imai K, Allard MA, Castro Benitez C, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Baba H, Adam R: Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. *Br J Surg* 104(5):570-579, 2017.
28. Ida S, Hiki N, Cho H, Sakamaki K, Ito S, Fujitani K, Takiguchi N, Kawashima Y, Nishikawa K, Sasako M, Aoyama T, Honda M, Sato T, Nunobe S, Yoshikawa T: Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer. *Br J Surg* 104(4):377-383, 2017.
29. Izumi D, Ishimoto T, Miyake K, Eto T, Arima K, Kiyozumi Y, Uchihara T, Kurashige J, Iwatsuki M, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N, Watanabe M, Goel A, Tan P, Baba H: Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc. *Stem Cells* 35(9):2027-2036, 2017.
30. Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA: Global chemotherapy development for gastric cancer. *Gastric Cancer* 20(1):92-101, 2017.
31. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA: Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. *Oncotarget* 8(45):79356-79365, 2017.
32. Hiyoshi Y, Akiyoshi T, Inoue R, Murofushi K, Yamamoto N, Fukunaga Y, Ueno M, Baba H, Mori S, Yamaguchi T: Serum miR-143 levels predict the pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. *Oncotarget* 8(45):79201-79211, 2017.
33. Gu M, Nishihara R, Chen Y, Li W, Shi Y, Masugi Y, Hamada T, Kosumi K, Liu L, da Silva A, Nowak JA, Twombly T, Du C, Koh H, Li W, Meyerhardt JA, Wolpin BM, Giannakis M, Aguirre AJ, Bass AJ, Drew DA, Chan AT, Fuchs CS, Qian ZR, Ogino S: Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. *Oncotarget* 8(50):87379-87389, 2017.
34. Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA: Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. *Oncotarget* 8(46):81430-81440, 2017.
35. Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, Song WM, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman SL, Hoshida Y, Prakash J: Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. *Exp Mol Med* 49(11):e396, 2017.
36. Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, Ruiz de Galarreta M, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, Lujambio A, Sanchez R, Fuchs BC, Poelstra K, Prakash J, Hoshida Y, Precision Liver Cancer Prevention C: Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. *Nanomedicine* 14(2):317-325, 2017.
37. Kusumoto T, Sunami E, Ota M, Yoshida K, Sakamoto Y, Tomita N, Maeda A, Mochizuki I, Okabe M, Kunieda K, Yamauchi J, Itabashi M, Kotake K, Takahashi K, Baba H, Boku N, Aiba K, Ishiguro M, Morita S, Sugihara K: Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. *Clin Colorectal Cancer* (Doi: 10.1016/j.clcc.2017.10.015), 2017.
38. Yamashita Y, Imai K, Tsujita E, Kaida T, Yamao Y, Umezaki N, Tsukamoto M, Kitano Y, Yamamura K, Arima K, Miyata T, Nakagawa S, Hashimoto D, Chikamoto A, Ishiko T, Baba H: Selective venous occlusions for reducing blood loss during right anterior sectionectomy of the liver for hepatocellular carcinoma. *J Am Coll Surg* 224(2):e5-9, 2017.
39. Nakanishi R, Kitao H, Kuniwa M, Morodomi Y, Iimori M, Kurashige J, Sugiyama M, Nakashima Y, Saeki H, Oki E, Maehara Y: Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication. *Sci Rep* 7(1):16969, 2017.
40. Zhou J, Hiki N, Mine S, Kumagai K, Ida S, Jiang X, Nunobe S, Ohashi M, Sano T, Yamaguchi T: Role of Prealbumin as a Powerful and Simple Index for Predicting Postoperative Complications After Gastric Cancer Surgery. *Ann Surg Oncol* 24(2):510-517, 2017.
41. Tsujiura M, Hiki N, Ohashi M, Nunobe S, Kumagai K, Ida S, Okumura Y, Sano T, Yamaguchi T: "Pancreas-Compressionless Gastrectomy": A Novel Laparoscopic Approach for Suprapancreatic Lymph Node Dissection. *Ann Surg Oncol* 24(11):3331-3337, 2017.
42. Tsujiura M, Hiki N, Ohashi M, Nunobe S, Kumagai K, Ida S, Hayami M, Sano T, Yamaguchi T: Excellent Long-Term Prognosis and Favorable Postoperative Nutritional Status After Laparoscopic Pylorus-Preserving Gastrectomy. *Ann Surg Oncol* 24(8):2233-2240, 2017.
43. Okabe H, Hashimoto D, Chikamoto A, Yoshida M, Taki K, Arima K, Imai K, Tamura Y, Ikeda O, Ishiko T, Uchiyama H, Ikegami T, Harimoto N, Itoh S, Yamashita Y, Yoshizumi T, Beppu T, Yamashita Y, Baba H, Maehara Y: Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators. *Ann Surg Oncol* 24(5):1399-1405, 2017.
44. Kudou K, Saeki H, Nakashima Y, Eda Hiro K, Korehisa S, Taniguchi D, Tsutsumi R, Nishimura S, Nakaji Y, Akiyama S, Tajiri H, Nakanishi R, Kurashige J, Sugiyama M, Oki E, Maehara Y: Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer. *Ann Surg Oncol* 24(7):1804-1810, 2017.
45. Hayami M, Hiki N, Nunobe S, Mine S, Ohashi M, Kumagai K, Ida S, Watanabe M, Sano T, Yamaguchi T: Clinical Outcomes and Evaluation of Laparoscopic Proximal Gastrectomy with Double-Flap Technique for Early Gastric Cancer in

- the Upper Third of the Stomach. *Ann Surg Oncol* 24(6):1635-1642, 2017.
46. Chikamoto A, Inoue R, Komohara Y, Sakamaki K, Hashimoto D, Shiraishi S, Takamori H, Yamashita Y, Yoshida N, Yamanaka T, Yamashita Y, Baba H: Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. *Ann Surg Oncol* 24(7):2040-2046, 2017.
 47. Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Harada K, Rogers JE, Mares J, Amlashi FG, Minsky BD, Das P, Hofstetter WL, Matamoros A, Jr., Sagebiel TL, Blum-Murphy MA, Lee JH, Weston B, Bhutani MS, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA: Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. *Ann Surg Oncol* 24(8):2291-2301, 2017.
 48. Li J, Xu R, Xu J, Denda T, Ikejiri K, Shen L, Toh Y, Shimada K, Kato T, Sakai K, Yamamoto M, Mishima H, Wang J, Baba H: Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. *Cancer Sci* 108(10):2045-2051, 2017.
 49. Koganemaru S, Inoshita N, Miura Y, Miyama Y, Fukui Y, Ozaki Y, Tomizawa K, Hanaoka Y, Toda S, Suyama K, Tanabe Y, Moriyama J, Fujii T, Matoba S, Kuroyanagi H, Takano T: Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. *Cancer Sci* 108(5):853-858, 2017.
 50. Uchiyama H, Yoshizumi T, Ikegami T, Harimoto N, Itoh S, Okabe H, Soejima Y, Maehara Y: Use of internal jugular vein grafts in reconstructing multiple venous orifices of right hepatic grafts without the middle hepatic vein trunk. *Liver Transpl* 23(1):110-6, 2017.
 51. Tsuji Y, Baba H, Takeda K, Kobayashi M, Oki E, Gotoh M, Yoshida K, Shimokawa M, Kakeji Y, Aiba K: Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. *Expert Opin Pharmacother* 18(8):753-758, 2017.
 52. Noh DY, Roh JK, Kim YH, Yoshida K, Baba H, Samson-Fernando MC, Misra S, Aziz Z, Umbas R, Y PS, Shu Kam Mok T, Yang HK, Akaza H: Symposium: "Oncology Leadership in Asia". *Cancer Res Treat* 49(2):283-291, 2017.
 53. Uchihara T, Yoshida N, Baba Y, Yagi T, Toihata T, Oda E, Kuroda D, Eto T, Ohuchi M, Nakamura K, Sawayama H, Kinoshita K, Iwatsuki M, Ishimoto T, Sakamoto Y, Baba H: Risk factors for pulmonary morbidities after minimally invasive esophagectomy for esophageal cancer. *Surg Endosc* (Doi: 10.1007/s00464-017-5993-z), 2017.
 54. Miyata T, Yamashita Y, Yamao T, Umezaki N, Tsukamoto M, Kitano Y, Yamamura K, Arima K, Kaida T, Nakagawa S, Imai K, Hashimoto D, Chikamoto A, Ishiko T, Asato T, Mikami Y, Aishima S, Baba H: Hepatobiliary and Pancreatic: Hepatocellular carcinoma developed with angiolipoma. *J Gastroenterol Hepatol* 32(3):547, 2017.
 55. Matsumura K, Hashimoto D, Umezaki N, Nakagawa S, Chikamoto A, Yamashita Y, Ikeda O, Yamashita Y, Baba H: Hepatobiliary and Pancreatic: Portal vein stent for local recurrence of bile duct cancer. *J Gastroenterol Hepatol* 32(8):1425, 2017.
 56. Mima K, Ogino S, Nakagawa S, Sawayama H, Kinoshita K, Krashima R, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Sakamoto Y, Yamashita Y, Yoshida N, Chikamoto A, Ishiko T, Baba H: The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. *Surg Oncol* 26(4):368-376, 2017.
 57. Kumai Y, Yoshida N, Kamenosono Y, Matsubara K, Samejima Y, Baba H, Yumoto E: Effects of Chin-Down Maneuver on the Parameters of Swallowing Function After Esophagectomy With 3-Field Lymphadenectomy Examined by Videofluoroscopy. *Arch Phys Med Rehabil* 98(6):1174-1179, 2017.
 58. Imamura T, Murakami Y, Nitta H: *Aeromonas sobria* serine protease (ASP): a subtilisin family endopeptidase with multiple virulence activities. *Biol Chem* 398(10):1055-1068, 2017.
 59. Miyamoto Y, Suyama K, Baba H: Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. *Int J Mol Sci* 18(4):E752, 2017.
 60. Mizrak Kaya D, Nogueras-Gonzalez GM, Harada K, Amlashi FG, Roy-Chowdhuri S, Estrella JS, Das P, Lee JH, Weston B, Bhutani MS, Matamoros A, Jr., Thomas I, Lin Q, Badgwell BD, Ajani JA: Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. *J Surg Oncol* (Doi: 10.1002/jso.24912), 2017.
 61. Imai K, Benitez CC, Allard MA, Vibert E, Cunha AS, Cherqui D, Castaing D, Bismuth H, Baba H, Adam R: Potential of a cure in patients with colorectal liver metastases and concomitant extrahepatic disease. *J Surg Oncol* 115(4):488-496, 2017.
 62. Hayami M, Watanabe M, Ishizuka N, Mine S, Imamura Y, Okamura A, Kuroguchi T, Yamashita K: Prognostic impact of postoperative pulmonary complications following salvage esophagectomy after definitive chemoradiotherapy. *J Surg Oncol* (Doi: 10.1002/jso.24941), 2017.
 63. Shi Y, Qian ZR, Zhang S, Li W, Masugi Y, Li T, Chan JA, Yang J, Da Silva A, Gu M, Liu L, Hamada T, Kosumi K, Dutton T, Brais LK, Nishihara R, Fuchs CS, Ogino S, Kulke MH: Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index. *Pancreas* 46(10):1347-1353, 2017.
 64. Hashimoto D, Chikamoto A, Masuda T, Nakagawa S, Imai K, Yamashita Y, Reber HA, Baba H: Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? *Pancreas* 46(9):1083-1090, 2017.
 65. Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA: Advanced gastric adenocarcinoma: optimizing therapy options. *Expert Rev Clin Pharmacol* 10(3):263-271, 2017.
 66. Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T: Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. *Cancer Chemother Pharmacol* 79(4):813-823, 2017.
 67. Satake H, Iwatsuki M, Uenosono Y, Shiraishi T, Tanioka H, Saeki H, Sugimachi K, Kitagawa D, Shimokawa M, Oki E, Emi Y, Kakeji Y, Tsuji A, Akagi Y, Natsugoe S, Baba H, Maehara Y, Kyushu Study Group of Clinical C: Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104). *Cancer Chemother Pharmacol* 79(1):147-153, 2017.
 68. Nakagawa S, Hashimoto D, Yamashita Y, Chikamoto A, Baba H: Prognostic nutrition index predict the recurrence of the patients who underwent curative surgery for pancreas ductal adenocarcinoma. *Pancreatol* 17(3):S64-S65, 2017.
 69. Hashimoto D, Nakagawa S, Umezaki N, Yamao T, Kitano Y, Yamamura K, Kaida T, Arima K, Imai K, Yamashita Y, Chikamoto A, Baba H: Efficacy and safety of postoperative anticoagulation prophylaxis with enoxaparin in patients undergoing pancreatic surgery: A prospective trial and literature review. *Pancreatol* 17(3):464-470, 2017.
 70. Kaibori M, Kon M, Kitawaki T, Kawaura T, Hasegawa K, Kokudo N, Ariizumi S, Beppu T, Ishizu H, Kubo S, Kamiyama T, Takamura H, Kobayashi T, Kim DS, Wang HJ, Kim JM, Han DH, Park SJ, Kang KJ, Hwang S, Roh Y, You YK, Joh JW, Yamamoto M: Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma. *J Hepatobiliary Pancreat Sci* 24(11):616-626, 2017.
 71. Beppu T, Imai K, Okuda K, Eguchi S, Kitahara K, Tani N, Ueno S, Shirabe K, Ohta M, Kondo K, Nanashima A,

- Noritomi T, Shiraishi M, Takami Y, Okamoto K, Kikuchi K, Baba H, Fujioka H: Anterior approach for right hepatectomy with hanging maneuver for hepatocellular carcinoma: a multi-institutional propensity score-matching study. *J Hepatobiliary Pancreat Sci* 24(3):127-136, 2017.
72. Tokunaga R, Akiyoshi T, Hiyoshi Y, Fukunaga Y, Ueno M: Laparoscopic resection of a tumour in the ischioanal fossa - a video vignette. *Colorectal Dis* 19(8):787-788, 2017.
 73. Yamashita K, Watanabe M, Mine S, Kuroguchi T, Okamura A, Hayami M, Imamura Y: Patterns and Outcomes of Recurrent Esophageal Cancer After Curative Esophagectomy. *World J Surg* 41(9):2337-2344, 2017.
 74. Okumura Y, Hiki N, Kumagai K, Ida S, Nunobe S, Ohashi M, Sano T: Postoperative Prolonged Inflammatory Response as a Poor Prognostic Factor After Curative Resection for Gastric Cancer. *World J Surg* 41(10):2611-2618, 2017.
 75. Okamura A, Watanabe M, Imamura Y, Kamiya S, Yamashita K, Kuroguchi T, Mine S: Preoperative Glycosylated Hemoglobin Levels Predict Anastomotic Leak After Esophagectomy with Cervical Esophago-gastric Anastomosis. *World J Surg* 41(2):200-207, 2017.
 76. Okamura A, Watanabe M, Imamura Y, Hayami M, Yamashita K, Kuroguchi T, Mine S: Glycemic Status and Prognosis of Patients with Squamous Cell Carcinoma of the Esophagus. *World J Surg* 41(10):2591-2597, 2017.
 77. Mine S, Watanabe M, Okamura A, Imamura Y, Kajiyama Y, Sano T: Superior Thoracic Aperture Size is Significantly Associated with Cervical Anastomotic Leakage After Esophagectomy. *World J Surg* 41(10):2598-2604, 2017.
 78. Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Baba Y, Sakamoto Y, Baba H: The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. *World J Surg* 41(2):480-486, 2017.
 79. Mizrak Kaya D, Dong X, Noguera-Gonzalez GM, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, Ajani JA: Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. *Med Oncol* 34(8):135, 2017.
 80. Arima K, Yamashita Y, Hashimoto D, Nakagawa S, Umezaki N, Yamao T, Tsukamoto M, Kitano Y, Yamamura K, Miyata T, Okabe H, Ishimoto T, Imai K, Chikamoto A, Baba H: Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. *Am J Surg* (Doi: 10.1016/j.amjsurg.2017.08.016), 2017.
 81. Kaida T, Nitta H, Kitano Y, Yamamura K, Arima K, Higashi T, Taki K, Nakagawa S, Okabe H, Hayashi H, Imai K, Hashimoto D, Yamashita Y, Chikamoto A, Ishiko T, Beppu T, Baba H: Preoperative platelet-to-lymphocyte ratio can predict recurrence beyond the Milan criteria after hepatectomy for patients with hepatocellular carcinoma. *Hepatol Res* 47(10):991-999, 2017.
 82. Itoh S, Yoshizumi T, Shirabe K, Kimura K, Okabe H, Harimoto N, Ikegami T, Uchiyama H, Nishie A, Maehara Y: Functional remnant liver assessment predicts liver-related morbidity after hepatic resection in patients with hepatocellular carcinoma. *Hepatol Res* 47(5):398-404, 2017.
 83. Hayashi H, Kuroki H, Higashi T, Takeyama H, Yokoyama N, Okabe H, Nitta H, Beppu T, Takamori H, Baba H: Thrombospondin-1 expression may be implicated in liver atrophic mechanism due to obstructed portal venous flow. *Hepatol Res* 47(8):803-812, 2017.
 84. Shigaki H, Imamura Y, Mine S, Okamura A, Kuroguchi T, Yamashita K, Watanabe M: Clinicopathological features of esophageal squamous cell carcinoma in never smoker-never drinkers. *Dis Esophagus* 30(5), 2017.
 85. Okamura A, Watanabe M, Mine S, Kuroguchi T, Yamashita K, Hayami M, Imamura Y, Ogura M, Ichimura T, Takahari D, Chin K: Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma. *Dis Esophagus* 30(9):1-8, 2017.
 86. Matsumoto A, Watanabe M, Mine S, Nishida K, Shigaki H, Kawabata K, Yanaga K, Sano T: Comparison of synchronous versus staged surgeries for patients with synchronous double cancers of the esophagus and head-and-neck. *Dis Esophagus* 30(1):1-6, 2017.
 87. Kosumi K, Baba Y, Yamashita K, Ishimoto T, Nakamura K, Ohuchi M, Kiyozumi Y, Izumi D, Tokunaga R, Harada K, Shigaki H, Kurashige J, Iwatsuki M, Sakamoto Y, Yoshida N, Watanabe M, Baba H: Monitoring sputum culture in resected esophageal cancer patients with preoperative treatment. *Dis Esophagus* 30(12):1-9, 2017.
 88. Baba Y, Saeki H, Nakashima Y, Oki E, Shigaki H, Yoshida N, Watanabe M, Maehara Y, Baba H: Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. *Dis Esophagus* 30(2):1-7, 2017.
 89. Baba Y, Baba H, Yamamoto S, Shimada H, Shibata T, Miyazaki T, Yoshikawa T, Nakajima Y, Tsuji Y, Shimokawa M, Kitagawa Y, Aiba K: Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. *Dis Esophagus* 30(2):1-7, 2017.
 90. Morinaga T, Imai K, Yamashita Y, Yamao T, Kaida T, Nakagawa S, Hashimoto D, Chikamoto A, Sumiyoshi S, Mikami Y, Baba H: Multicystic biliary hamartoma with extremely elevated CA19-9: a case report. *Scand J Gastroenterol* 52(8):916-919, 2017.
 91. Tokunaga R, Sakamoto Y, Nakagawa S, Ohuchi M, Izumi D, Kosumi K, Taki K, Higashi T, Miyamoto Y, Yoshida N, Oki E, Watanabe M, Baba H: CONUT: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. *Int J Colorectal Dis* 32(1):99-106, 2017.
 92. Yoshida N, Baba Y, Baba H: Preoperative malnutrition and prognosis after neoadjuvant chemotherapy followed by subsequent esophagectomy. *J Thorac Dis* 9(10):3437-3439, 2017.
 93. Watanabe M: Transcription factor SPZ1 may promote TWIST-mediated epithelial-mesenchymal transition in thoracic malignancies. *J Thorac Dis* 9(9):2740-2742, 2017.
 94. Maeda K, Akagi J: Cognitive impairment is independently associated with definitive and possible sarcopenia in hospitalized older adults: The prevalence and impact of comorbidities. *Geriatr Gerontol Int* 17(7):1048-1056, 2017.
 95. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Jr., Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA: 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. *Oncology* 93(4):243-248, 2017.
 96. Yoshida N, Harada K, Baba Y, Kosumi K, Iwatsuki M, Kinoshita K, Nakamura K, Sakamoto Y, Miyamoto Y, Karashima R, Mima K, Sawayama H, Ohuchi M, Chikamoto A, Imamura Y, Watanabe M, Baba H: Preoperative controlling nutritional status (CONUT) is useful to estimate the prognosis after esophagectomy for esophageal cancer. *Langenbecks Arch Surg* 402(2):333-341, 2017.
 97. Okamura A, Watanabe M, Yamashita K, Yuda M, Hayami M, Imamura Y, Mine S: Implication of visceral obesity in patients with esophageal squamous cell carcinoma. *Langenbecks Arch Surg* (Doi: 10.1007/s00423-017-1643-0), 2017.
 98. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA: Translating genomic profiling to gastrointestinal cancer treatment. *Future Oncol* 13(10):919-934, 2017.
 99. Taguchi N, Oda S, Imuta M, Yamamura S, Nakaura T, Utsunomiya D, Kidoh M, Nagayama Y, Yuki H, Hirata K, Iyama Y,

- Funama Y, Baba H, Yamashita Y: Model-based Iterative Reconstruction in Low-radiation-dose Computed Tomography Colonography: Preoperative Assessment in Patients with Colorectal Cancer. *Acad Radiol* (Doi: 10.1016/j.acra.2017.10.008), 2017.
100. Tokunaga R, Sakamoto Y, Nakagawa S, Izumi D, Kosumi K, Taki K, Higashi T, Miyata T, Miyamoto Y, Yoshida N, Baba H: Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection. *Int J Clin Oncol* 22(4):740-748, 2017.
 101. Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M, Japan CSGo: Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. *Int J Clin Oncol* 22(2):405-412, 2017.
 102. Nakamura K, Yoshida N, Baba Y, Kosumi K, Uchihara T, Kiyozumi Y, Ohuchi M, Ishimoto T, Iwatsuki M, Sakamoto Y, Watanabe M, Baba H: Elevated preoperative neutrophil-to-lymphocytes ratio predicts poor prognosis after esophagectomy in T1 esophageal cancer. *Int J Clin Oncol* 22(3):469-475, 2017.
 103. Miyata T, Yamashita Y, Yamao T, Umezaki N, Tsukamoto M, Kitano Y, Yamamura K, Arima K, Kaida T, Nakagawa S, Imai K, Hashimoto D, Chikamoto A, Ishiko T, Baba H: Prognostic impacts of postoperative complications in patients with intrahepatic cholangiocarcinoma after curative operations. *Int J Clin Oncol* 22(3):526-532, 2017.
 104. Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y: Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). *Int J Clin Oncol* (Doi: 10.1007/s10147-017-1212-0), 2017.
 105. Minami K, Morita M, Emi Y, Okamoto M, Tanaka E, Nagata S, Touyama T, Ohgaki K, Tanaka T, Okumura H, Suenaga T, Tokunaga S, Oki E, Kakeji Y, Akagi Y, Baba H, Natsugoe S, Maehara Y, Kyushu Study Group of Clinical C: Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan. *Int J Clin Oncol* 22(3):505-510, 2017.
 106. Kitano Y, Iwatsuki M, Kurashige J, Kuroda D, Kosumi K, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N, Haga Y, Baba H: Estimation of Physiologic Ability and Surgical Stress (E-PASS) versus modified E-PASS for prediction of postoperative complications in elderly patients who undergo gastrectomy for gastric cancer. *Int J Clin Oncol* 22(1):80-87, 2017.
 107. Higashi T, Hayashi H, Taki K, Sakamoto K, Kuroki H, Nitta H, Hashimoto D, Chikamoto A, Beppu T, Baba H: Erratum to: Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy. *Int J Clin Oncol* 22(5):986-990, 2017.
 108. Arima K, Okabe H, Hashimoto D, Chikamoto A, Nitta H, Higashi T, Kaida T, Yamamura K, Kitano Y, Komohara Y, Yamashita Y, Beppu T, Takeya M, Baba H: Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors. *Int J Clin Oncol* 22(4):734-739, 2017.
 109. Ando K, Emi Y, Suenaga T, Hamanoue M, Maekawa S, Sakamoto Y, Kai S, Satake H, Shimose T, Shimokawa M, Saeki H, Oki E, Sakai K, Akagi Y, Baba H, Maehara Y, Kyushu Study Group of Clinical C: A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). *Int J Clin Oncol* 22(5):913-920, 2017.
 110. Yamashita Y, Tsujita E, Chikamoto A, Imai K, Kaida T, Yamao T, Umezaki N, Nakagawa S, Hashimoto D, Baba H: Linear Stapling Device with Pre-attached Bioabsorbable Polyglycolic Acid Felt Reduces Postoperative Pancreatic Fistula After Distal Pancreatectomy. *Anticancer Res* 37(4):1865-1868, 2017.
 111. Tsukamoto M, Yamashita Y, Imai K, Umezaki N, Yamao T, Okabe H, Nakagawa S, Hashimoto D, Chikamoto A, Ishiko T, Yoshizumi T, Maehara Y, Baba H: Predictors of Cure of Intrahepatic Cholangiocarcinoma After Hepatic Resection. *Anticancer Res* 37(12):6971-6975, 2017.
 112. Miyata T, Yamashita Y, Yamao T, Umezaki N, Tsukamoto M, Kitano Y, Yamamura K, Arima K, Kaida T, Nakagawa S, Imai K, Hashimoto D, Chikamoto A, Ishiko T, Baba H: Clinical Benefits of Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: A Retrospective Single-institution Study. *Anticancer Res* 37(5):2673-2677, 2017.
 113. Miyata T, Beppu T, Higashi T, Nakagawa S, Okabe H, Imai K, Yamashita Y, Chikamoto A, Baba H: A Glissonean Approach with Individual Isolation During Right Hemi-Hepatectomy After Portal Vein Embolization. *Anticancer Res* 37(12):7069-7071, 2017.
 114. Kitano Y, Yamashita Y, Yamamura K, Arima K, Kaida T, Miyata T, Nakagawa S, Mima K, Imai K, Hashimoto D, Chikamoto A, Baba H: Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma. *Anticancer Res* 37(6):3229-3237, 2017.
 115. Yamamura K, Kosumi K, Baba Y, Harada K, Gao F, Zhang X, Zhou L, Kitano Y, Arima K, Kaida T, Takeyama H, Higashi T, Imai K, Hashimoto D, Chikamoto A, Tan X, Baba H: LINE-1 methylation level and prognosis in pancreas cancer: pyrosequencing technology and literature review. *Surg Today* 47(12):1450-1459, 2017.
 116. Tokunaga R, Sakamoto Y, Nakagawa S, Yoshida N, Baba H: The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment. *Surg Today* 47(5):636-642, 2017.
 117. Taki K, Hashimoto D, Nakagawa S, Ozaki N, Tomiyasu S, Ohmuraya M, Arima K, Kaida T, Higashi T, Sakamoto K, Sakata K, Okabe H, Nitta H, Hayashi H, Chikamoto A, Beppu T, Takamori H, Hirota M, Baba H: Significance of lymph node metastasis in pancreatic neuroendocrine tumor. *Surg Today* 47(9):1104-1110, 2017.
 118. Nitta H, Nakagawa S, Kaida T, Arima K, Higashi T, Taki K, Okabe H, Hayashi H, Hashimoto D, Chikamoto A, Ishiko T, Beppu T, Baba H: Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma. *Surg Today* 47(3):375-384, 2017.
 119. Maehara Y, Shirabe K, Kohnoe S, Emi Y, Oki E, Kakeji Y, Baba H, Ikeda M, Kobayashi M, Takayama T, Natsugoe S, Haraguchi M, Yoshida K, Terashima M, Sasako M, Yamaue H, Kokudo N, Uesaka K, Uemoto S, Kosuge T, Sawa Y, Shimada M, Doki Y, Yamamoto M, Taketomi A, Takeuchi M, Akazawa K, Yamanaka T, Shimokawa M: Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial. *Surg Today* 47(9):1060-1071, 2017.
 120. Maehara Y, Shirabe K, Kohnoe S, Emi Y, Oki E, Kakeji Y, Baba H, Ikeda M, Kobayashi M, Takayama T, Natsugoe S, Haraguchi M, Yoshida K, Terashima M, Sasako M, Yamaue H, Kokudo N, Uesaka K, Uemoto S, Kosuge T, Sawa Y, Shimada M, Doki Y, Yamamoto M, Taketomi A, Takeuchi M, Akazawa K, Yamanaka T, Shimokawa M: Erratum to: Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial. *Surg Today* 47(12):1539-1540, 2017.
 121. Kuramoto M, Ikeshima S, Yamamoto K, Morita K, Uchihara T, Itouyama R, Yoshimatsu S, Shimada S, Baba H: The intentional oblique transection double stapling technique in anterior resection for rectal cancer. *Surg Today* 47(4):525-528, 2017.
 122. Hashimoto D, Chikamoto A, Harimoto N, Ikegami T, Uchiyama H, Yoshizumi T, Baba H, Maehara Y: A comparative study on the complications of conventional and end-to-side inserting pancreaticoduodenectomy.

- Surg Today* 47(2):238-244, 2017.
123. Ogata K, Takamori H, Umezaki N, Yagi T, Ogawa K, Ozaki N, Hayashi H, Tanaka H, Ikuta Y, Doi K: Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer. *J Chemother* 29(5):314-316, 2017.
 124. Suyama K, Fujiwara S, Takeshita T, Sueta A, Inao T, Yamamoto-Ibusuki M, Yamamoto Y, Iwase H: Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer. *Mol Clin Oncol* 7(1):24-26, 2017.
 125. Yamamura K, Baba Y, Miyake K, Nakamura K, Shigaki H, Mima K, Kurashige J, Ishimoto T, Iwatsuki M, Sakamoto Y, Yamashita Y, Yoshida N, Watanabe M, Baba H: Fusobacterium nucleatum in gastroenterological cancer: Evaluation of measurement methods using quantitative polymerase chain reaction and a literature review. *Oncol Lett* 14(6):6373-6378, 2017.
 126. Yamashita Y, Baba H: How can we predict hepatic insufficiency after resection of colorectal liver metastases? *Transl Cancer Res* 6(S9):S1435-S1438, 2017.
 127. Suyama K, Miura Y, Takano T, Iwase H: Chemotherapy for Patients with Renal Dysfunction. *J Clin Exp Oncol* 6(1), 2017.
 128. Miyamoto Y, Zhang W, Lenz HJ: Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. *Indian J Surg Oncol* 8(4):580-590, 2017.
 129. Shichino T, Hirao M, Haga Y: Inter-rater reliability of the American Society of Anesthesiologists physical status rating for emergency gastrointestinal surgery. *Acute Med Surg* 4(2):161-165, 2017.
 130. Baba Y, Iwatsuki M, Yoshida N, Watanabe M, Baba H: Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implications. *Ann Gastroenterol Surg* 1(2):99-104, 2017.
 131. Shimada H, Fukagawa T, Haga Y, Oba K: Does postoperative morbidity worsen the oncological outcome after radical surgery for gastrointestinal cancers? A systematic review of the literature. *Ann Gastroenterol Surg* 1(1):11-23, 2017.
 132. Yamashita Y, Shirabe K, Beppu T, Eguchi S, Nanashima A, Ohta M, Ueno S, Kondo K, Kitahara K, Shiraishi M, Takami Y, Noritomi T, Okamoto K, Ogura Y, Baba H, Fujioka H: Surgical Management of Recurrent Intrahepatic Cholangiocarcinoma; Predictors, Adjuvant Chemotherapy, and Surgical Therapy for Recurrence: A Multi-Institutional Study by the Kyushu Study Group of Liver Surgery. *Ann Gastroenterol Surg* 1(2):136-142, 2017.
 133. Koga Y, Beppu T, Kuramoto K, Kinoshita K, Yoshida Y, Imai K, Takahara T, Nakamura M, Wakabayashi G, Baba H: Comparison of laparoscopic versus open liver resection for hepatocellular carcinoma using propensity score matching. *Ann Laparosc Endosc Surg* 2017(2):105, 2017.
 134. Tomiguchi J, Miyamoto H, Ozono K, Gushima R, Shono T, Naoe H, Tanaka M, Baba H, Katabuchi H, Sasaki Y: Preoperative Diagnosis of Intestinal Endometriosis by Magnifying Colonoscopy and Target Biopsy. *Case Rep Gastroenterol* 11(2):494-499, 2017.
 135. Harada K, Mizrak Kaya D, Song S, Baba H, Ajani JA: Genomic profiling of colorectal cancers and the future of personalized treatment. *Colorectal Cancer* (Doi: 10.2217/crc-2016-0017), 2017.
 136. Baba H, Yamada Y, Takahashi D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K: S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomized phase 3: SOFT study. *ESMO Open* 2(1):e000135, 2017.
 137. Harada K, Mizrak Kaya D, Baba H, Ajani JA: Recent advances in preoperative management of esophageal adenocarcinoma. *F1000Res* 6:501, 2017.
 138. Ezo S, Noda H, Akahane N, Sato O, Hama T, Miyata T, Terahara T, Fujishita M, Sakamoto H, Abe SK, Gilmour S, Shobayashi T: Trends in policy on the prevention and control of non-communicable diseases in Japan. *Health Systems & Reform* 3(4):268-277, 2017.
 139. Yamashita Y, Imai K, Mima K, Nakagawa S, Hashimoto D, Chikamoto A, Baba H: Idiosyncratic drug-induced liver injury: A short review. *Hepatol Commun* 1(6):494-500, 2017.
 140. Tokunaga R, Sakamoto Y, Nakagawa S, Miyamoto Y, Yoshida N, Baba H: Para-sacral approach for large gastrointestinal stromal tumor of the lower rectum. *Int Canc Conf J* (Doi: 10.1007/s13691-017-0314-x), 2017.
 141. Yamane T, Imai K, Uchiba M, Umezaki N, Yamao T, Kaida T, Nakagawa S, Hashimoto D, Yamashita Y, Chikamoto A, Yoshida N, Baba H: Acquired factor V deficiency following transcatheter arterial chemoembolization for hepatocellular carcinoma: a case report. *Int Canc Conf J* 6(3):126-130, 2017.
 142. Beppu T, Nakagawa S, Nitta H, Okabe H, Kaida T, Imai K, Hayashi H, Koga Y, Kuramoto K, Hashimoto D, Yamashita Y, Chikamoto A, Ishiko T, Baba H: The Number of Positive Tumor Marker Status Is Beneficial for the Selection of Therapeutic Modalities in Patients with Hepatocellular Carcinoma. *J Clin Transl Hepatol* 5(2):165-168, 2017.
 143. Sugita H, Akiyama T, Daitoku N, Tashima R, Tanaka H, Honda S, Arita T, Yagi Y, Hirota M: Internal hernia after laparoscopic right hemicolectomy, report of a case. *J Surg Case Rep* 2017(5):rjw217, 2017.
 144. Hayata M, Yamashita J, Tokunaga K, Ejima M, Sagishima K, Nakagawa S, Hashimoto D, Baba H, Maruyama K, Kohrogi Y, Mizumoto T, Mukoyama M, Kamohara H: Refractory peritonitis by spontaneous perforation of the common bile duct in a patient receiving peritoneal dialysis. *Renal Replacement Therapy* 3(1), 2017.
 145. Harada K, Song S, Baba H, Ajani JA: Is phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway therapeutic target for esophageal adenocarcinoma. *Shanghai Chest* 2017(1):51, 2017.
 146. Kitano Y, Kuramoto M, Masuda T, Kuroda D, Yamamoto K, Ikeshima S, Iyama KI, Shimada S, Baba H: Ascending colon cancer with synchronous external iliac and inguinal lymph node metastases but without regional lymph node metastasis: a case report and brief literature review. *Surg Case Rep* 3(1):32, 2017.
 147. Miyata T, Okabe H, Chikamoto A, Yamao T, Umezaki N, Tsukamoto M, Kitano Y, Arima K, Nakagawa S, Imai K, Hashimoto D, Yamashita Y, Baba H: A long-term survivor of hilar cholangiocarcinoma with resection of recurrent peritoneal dissemination after R0 surgery: a case report. *Surg Case Rep* 3(1):110, 2017.
 148. Sawayama H, Miyanari N, Sugihara H, Iwagami S, Mizumoto T, Kubota T, Haga Y, Baba H: A fascia lata free flap in pelvic exenteration for Fournier gangrene due to advanced rectal cancer: a case report. *Surg Case Rep* 3(1):74, 2017.
 149. Sawayama H, Yoshida N, Miyamoto Y, Uchihara T, Toihata T, Yagi T, Hiyoshi Y, Iwatsuki M, Baba Y, Baba H: Primary colonic well-differentiated / dedifferentiated liposarcoma of the ascending colon: a case report. *Surg Case Rep* 3(1):96, 2017.
 150. Yagi T, Hashimoto D, Taki K, Yamamura K, Chikamoto A, Ohmuraya M, Beppu T, Baba H: Surgery for metastatic tumors of the pancreas. *Surg Case Rep* 3(1):31, 2017.
 151. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud

- A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV: Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. *Cancer Discov* 8(1):37-48, 2018.
152. Ozawa T, Kandimalla R, Gao F, Nozawa H, Hata K, Nagata H, Okada S, Izumi D, Baba H, Fleshman J, Wang X, Watanabe T, Goel A: A MicroRNA Signature Associated With Metastasis of T1 Colorectal Cancers to Lymph Nodes. *Gastroenterology* 154(4):844-848 e7, 2018.
153. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ: A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. *Clin Cancer Res* 24(4):784-793, 2018.
154. Beppu T, Yamamoto M: Laparoscopic Versus Open Liver Resection for Colorectal Liver Metastases-Which Is a More Suitable Standard Practice? *Ann Surg* 267(2):208-209, 2018.
155. Baba Y, Yoshida N, Kinoshita K, Iwatsuki M, Yamashita Y, Chikamoto A, Watanabe M, Baba H: Clinical and Prognostic Features of Patients With Esophageal Cancer and Multiple Primary Cancers: A Retrospective Single-institution Study. *Ann Surg* 267(3):478-483, 2018.
156. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ: CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. *Cancer Treat Rev* 63:40-47, 2018.
157. Hamada T, Soong TR, Masugi Y, Kosumi K, Nowak JA, da Silva A, Mu XJ, Twombly TS, Koh H, Yang J, Song M, Liu L, Gu M, Shi Y, Noshio K, Morikawa T, Inamura K, Shukla SA, Wu CJ, Garraway LA, Zhang X, Wu K, Meyerhardt JA, Chan AT, Glickman JN, Rodig SJ, Freeman GJ, Fuchs CS, Nishihara R, Giannakis M, Ogino S: TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. *Oncol Immunology* (Doi: 10.1080/2162402x.2018.1442999), 2018.
158. Kitano Y, Baba Y, Nakagawa S, Miyake K, Iwatsuki M, Ishimoto T, Yamashita Y, Yoshida N, Watanabe M, Nakao M, Baba H: Nrf2 promotes oesophageal cancer cell proliferation via metabolic reprogramming and detoxification of reactive oxygen species. *J Pathol* 244(3):346-357, 2018.
159. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA: Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. *Br J Cancer* 118(3):331-337, 2018.
160. Kitano Y, Okabe H, Yamashita Y, Nakagawa S, Saito Y, Umezaki N, Tsukamoto M, Yamao T, Yamamura K, Arima K, Kaida T, Miyata T, Mima K, Imai K, Hashimoto D, Komohara Y, Chikamoto A, Ishiko T, Baba H: Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. *Br J Cancer* 118(2):171-180, 2018.
161. Kuroda D, Sawayama H, Kurashige J, Iwatsuki M, Eto T, Tokunaga R, Kitano Y, Yamamura K, Ouchi M, Nakamura K, Baba Y, Sakamoto Y, Yamashita Y, Yoshida N, Chikamoto A, Baba H: Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. *Gastric Cancer* 21(2):204-212, 2018.
162. Kumagai K, Sano T, Hiki N, Nunobe S, Tsujiura M, Ida S, Ohashi M, Yamaguchi T: Survival benefit of "D2-plus" gastrectomy in gastric cancer patients with duodenal invasion. *Gastric Cancer* 21(2):296-302, 2018.
163. Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, Sudo K, Onodera H, Suzuki K, Suzuki A, Johnson RL, Wang Z, Song S, Ajani JA: Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. *Gastric Cancer* 21(1):31-40, 2018.
164. Hirschfield H, Bian CB, Higashi T, Nakagawa S, Zeleke TZ, Nair VD, Fuchs BC, Hoshida Y: In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. *Exp Mol Med* 50(1):e419, 2018.
165. Yoshida N, Baba H: The C-Reactive Protein/Albumin Ratio May Predict the Long-Term Outcome in Patients with Malignant Pleural Mesothelioma. *Ann Surg Oncol* (Doi: 10.1245/s10434-018-6420-y), 2018.
166. Okamura A, Watanabe M, Imamura Y, Hayami M, Yuda M, Yamashita K, Shoji Y, Mine S: Cervicofascioscopic Approach in Esophagectomy. *Ann Surg Oncol* 25(1):333, 2018.
167. Arima K, Komohara Y, Bu L, Tsukamoto M, Itoyama R, Miyake K, Uchihara T, Ogata Y, Nakagawa S, Okabe H, Imai K, Hashimoto D, Chikamoto A, Yamashita Y, Baba H, Ishimoto T: Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1beta from activated macrophages leads to poor prognosis in pancreatic cancer. *Cancer Sci* 109(2):462-470, 2018.
168. Ning Y, Zhang W, Hanna DL, Yang D, Okazaki S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, El-Khoueiry A, Lenz HJ: Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. *Pharmacogenomics J* 18(1):29-34, 2018.
169. Irino T, Sano T, Hiki N, Ohashi M, Nunobe S, Kumagai K, Ida S, Yamaguchi T: Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. *Surg Endosc* 32(1):268-275, 2018.
170. Haga Y, Hato S, Ikenaga M, Yamamoto K, Tsuburaya A, Doi K, Ikejiri K, Hirata T, Yamamoto M, Ishikawa S, Takeuchi H: Validation of an assessment tool: Estimation of Postoperative Overall Survival for Gastric Cancer. *Eur J Surg Oncol* 44(4):515-523, 2018.
171. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA: Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. *Target Oncol* 13(1):99-106, 2018.
172. Yamao T, Imai K, Yamashita Y, Kaida T, Nakagawa S, Mima K, Hashimoto D, Chikamoto A, Ishiko T, Baba H: Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation? *HPB (Oxford)* 20(3):244-250, 2018.
173. Saeki H, Emi Y, Oki E, Tokunaga S, Kakeji Y, Akagi Y, Baba H, Baba E, Maehara Y, Kyushu Study group of Clinical C: Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy. *BMC Cancer* 18(1):57, 2018.
174. Masuda T, Dann AM, Elliott IA, Baba H, Kim S, Sedarat A, Muthusamy VR, Girgis MD, Joe Hines O, Reber HA, Donahue TR: A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer. *J Gastrointest Surg* 22(2):295-302, 2018.
175. Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ: NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. *PLoS One* 13(3):e0193640, 2018.
176. Sakamoto K, Honda G, Beppu T, Kotake K, Yamamoto M, Takahashi K, Endo I, Hasegawa K, Itabashi M, Hashiguchi Y, Kotera Y, Kobayashi S, Yamaguchi T, Morita S, Miyazaki M, Sugihara K, Joint Committee for Nationwide Survey on

- Colorectal Liver M: Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan. *J Hepatobiliary Pancreat Sci* 25(2):115-123, 2018.
177. Yoshida N, Nakamura K, Kuroda D, Baba Y, Miyamoto Y, Iwatsuki M, Hiyoshi Y, Ishimoto T, Imamura Y, Watanabe M, Baba H: Preoperative Smoking Cessation is Integral to the Prevention of Postoperative Morbidities in Minimally Invasive Esophagectomy. *World J Surg* (Doi: 10.1007/s00268-018-4572-3), 2018.
 178. Miyata T, Yamashita Y, Higashi T, Taki K, Izumi D, Kosumi K, Tokunaga R, Nakagawa S, Okabe H, Imai K, Hashimoto D, Chikamoto A, Baba H: The Prognostic Impact of Controlling Nutritional Status (CONUT) in Intrahepatic Cholangiocarcinoma Following Curative Hepatectomy: A Retrospective Single Institution Study. *World J Surg* 42(4):1085-1091, 2018.
 179. Kiyozumi Y, Yoshida N, Ishimoto T, Yagi T, Koga Y, Uchihara T, Sawayama H, Hiyoshi Y, Iwatsuki M, Baba Y, Miyamoto Y, Watanabe M, Matsuyama T, Oya N, Baba H: Prognostic Factors of Salvage Esophagectomy for Residual or Recurrent Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy. *World J Surg* (Doi: 10.1007/s00268-018-4536-7), 2018.
 180. Tsukamoto M, Nitta H, Imai K, Higashi T, Nakagawa S, Okabe H, Arima K, Kaida T, Taki K, Hashimoto D, Chikamoto A, Ishiko T, Beppu T, Baba H: Clinical significance of half-lives of tumor markers alpha-fetoprotein and des-gamma-carboxy prothrombin after hepatectomy for hepatocellular carcinoma. *Hepatol Res* 48(3):E183-E193, 2018.
 181. Nakagawa S, Umezaki N, Yamao T, Kaida T, Okabe H, Mima K, Imai K, Hashimoto D, Yamashita Y, Ishiko T, Chikamoto A, Baba H: Survival impact of lymphocyte infiltration into the tumor of hepatocellular carcinoma in hepatitis B virus-positive or non-B non-C patients who underwent curative resection. *Hepatol Res* 48(3):E126-E132, 2018.
 182. Kosumi K, Yoshida N, Okadome K, Eto T, Kuroda D, Ohuchi M, Kiyozumi Y, Nakamura K, Izumi D, Tokunaga R, Harada K, Mima K, Sawayama H, Ishimoto T, Iwatsuki M, Baba Y, Miyamoto Y, Watanabe M, Baba H: Minimally invasive esophagectomy may contribute to long-term respiratory function after esophagectomy for esophageal cancer. *Dis Esophagus* (Doi: 10.1093/dote/dox153), 2018.
 183. Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H: Pyloroplasty may reduce weight loss 1 year after esophagectomy. *Dis Esophagus* 31(3):1-8, 2018.
 184. Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraiishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y, Kyushu Study Group of Clinical C: Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). *Oncology* (Doi: 10.1159/000486624), 2018.
 185. Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA: Liquid biopsies in gastrointestinal malignancies: when is the big day? *Expert Rev Anticancer Ther* 18(1):19-38, 2018.
 186. Baba Y, Yagi T, Sawayama H, Hiyoshi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Baba H: Long Interspersed Element-1 Methylation Level as a Prognostic Biomarker in Gastrointestinal Cancers. *Digestion* 97(1):26-30, 2018.
 187. Ikeda O, Inoue S, Tamura Y, Yamashita Y, Baba H, Inomata Y, Yamashita Y: Shunt-preserving disconnection of the portal to systemic circulation in patients with hepatic encephalopathy. *Acta Radiol* 59(4):441-447, 2018.
 188. Tsukamoto M, Yamashita Y, Imai K, Umezaki N, Yamao T, Kaida T, Mima K, Nakagawa S, Hashimoto D, Chikamoto A, Ishiko T, Baba H: Long-term Favorable Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma as an Initial Treatment: A Single-center Experience Over a 10-Year Period. *Anticancer Res* 38(2):1047-1052, 2018.
 189. Miyamoto Y, Oki E, Emi Y, Tokunaga S, Shimokawa M, Ogata Y, Akagi Y, Sakamoto Y, Tanaka T, Saeki H, Maehara Y, Baba H: Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer. *Anticancer Res* 38(1):491-499, 2018.
 190. Kuramoto K, Beppu T, Nitta H, Imai K, Masuda T, Miyata T, Koga Y, Kitano Y, Kaida T, Nakagawa S, Okabe H, Hayashi H, Hashimoto D, Yamashita Y, Chikamoto A, Kikuchi K, Baba H: Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination. *Anticancer Res* 38(1):525-531, 2018.
 191. Kinoshita K, Beppu T, Miyata T, Kuramoto K, Yoshida Y, Umesaki N, Kitano Y, Nakagawa S, Okabe H, Nitta H, Imai K, Hayashi H, Yamashita Y, Komori H, Horino K, Misumi A, Baba H: A Case of 15-Year Recurrence-free Survival After Microwave Coagulation Therapy for Liver Metastasis from Gastric Cancer. *Anticancer Res* 38(3):1595-1598, 2018.
 192. Imai K, Yamashita Y, Yusa T, Nakao Y, Itoyama R, Nakagawa S, Okabe H, Chikamoto A, Ishiko T, Baba H: Microvascular Invasion in Small-sized Hepatocellular Carcinoma: Significance for Outcomes Following Hepatectomy and Radiofrequency Ablation. *Anticancer Res* 38(2):1053-1060, 2018.
 193. Umezaki N, Hashimoto D, Nakagawa S, Kitano Y, Yamamura K, Chikamoto A, Matsumura F, Baba H: Number of acinar cells at the pancreatic stump predicts pancreatic fistula after pancreaticoduodenectomy. *Surg Today* (Doi: 10.1007/s00595-018-1656-5), 2018.
 194. Tokunaga R, Sakamoto Y, Nakagawa S, Miyamoto Y, Yoshida N, Baba H: Additional lymph node dissection for primary colorectal cancer invading another colon region. *Surg Today* (Doi: 10.1007/s00595-018-1641-z), 2018.
 195. Takeyama H, Beppu T, Higashi T, Kaida T, Arima K, Taki K, Imai K, Nitta H, Hayashi H, Nakagawa S, Okabe H, Hashimoto D, Chikamoto A, Ishiko T, Tanaka M, Sasaki Y, Baba H: Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma. *Surg Today* 48(4):431-438, 2018.
 196. Nakanishi R, Oki E, Sasaki S, Hirose K, Jogo T, Edahiro K, Korehisa S, Taniguchi D, Kudo K, Kurashige J, Sugiyama M, Nakashima Y, Ohgaki K, Saeki H, Maehara Y: Sarcopenia is an independent predictor of complications after colorectal cancer surgery. *Surg Today* 48(2):151-157, 2018.
 197. Torzilli G, Viganò L, Cimino M, Imai K, Vibert E, Donadon M, Mansour D, Castaing D, Adam R: Is Enhanced One-Stage Hepatectomy a Safe and Feasible Alternative to the Two-Stage Hepatectomy in the Setting of Multiple Bilobar Colorectal Liver Metastases? A Comparative Analysis between Two Pioneering Centers. *Dig Surg* (Doi: 10.1159/000486210), 2018.
 198. Baba H: Editorial. *Ann Gastroenterol Surg* 2(1):4-5, 2018.
 199. Yamashita Y, Imai K, Yusa T, Nakao Y, Kitano Y, Nakagawa S, Okabe H, Chikamoto A, Ishiko T, Yoshizumi T, Aishima S, Maehara Y, Baba H: Microvascular invasion of single small hepatocellular carcinoma ≤ 3 cm: Predictors and optimal treatments. *Ann Gastroenterol Surg* (Doi: 10.1002/ags3.12057), 2018.
 200. Ida S, Hiki N: Laparoscopic-assisted total gastrectomy for esophagogastric junctional adenocarcinoma. *Ann Laparosc Endosc Surg* 2018(3):16, 2018.
 201. Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA: Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. *Ann Transl Med* 6(4):80, 2018.
 202. Lopez A, Harada K, Kaya DM, Ajani JA: Current therapeutic landscape for advanced gastroesophageal cancers. *Ann Transl Med* 6(4):78, 2018.
 203. Sakamoto Y, Hiyoshi Y, Sakata K, Toyama E, Takata N, Yoshinaka I, Harada K, Baba H: Case of cecal volvulus successfully treated with endoscopic colopexy. *Asian J Endosc Surg* (Doi: 10.1111/ases.12460), 2018.

204. Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA: Customization of therapy for gastroesophageal adenocarcinoma patients. *Chronic Dis Transl Med* 4(1):8-17, 2018.
205. Sawayama H, Ishimoto T, Baba H: Microenvironment in the pathogenesis of gastric cancer metastasis. *J Cancer Metastasis Treat* (Doi: 10.20517/2394-4722.2017.79), 2018.
206. Uchihara T, Ishimoto T, Yonemura A, Baba H: Therapeutic targets against gastric cancer stem cells interacting with tumor microenvironment. *J Cancer Metastasis Treat* (Doi: 10.20517/2394-4722.2017.81), 2018.
207. Miyata T, Beppu T, Kuramoto K, Nakagawa S, Imai K, Hashimoto D, Namimoto T, Yamashita Y, Chikamoto A, Yamashita Y, Baba H: Hepatic sclerosed hemangioma with special attention to diffusion-weighted magnetic resonance imaging. *Surg Case Rep* 4(1):3, 2018.
208. Shimizu K, Hashimoto D, Umezaki N, Nakagawa S, Yamamura K, Chikamoto A, Matsumura F, Baba H: Thoracic wall muscle metastasis from pancreatic cancer. *Surg Case Rep* 4(1):12, 2018.
209. Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher S, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao W-l, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong K-K, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ: Amplification of wild-type KRAS drives intrinsic adaptive resistance to MEK inhibition in gastroesophageal cancer. *Nat Med* (in press)
210. Kiyozumi Y, Baba Y, Okadome K, Yagi T, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Komohara Y, Baba H: IDO1 expression is associated with immune tolerance and poor prognosis in patients with surgically resected esophageal cancer. *Ann Surg* (in press)
211. Kiyozumi Y, Iwatsuki M, Kurashige J, Ogata Y, Yamashita K, Koga Y, Toihata T, Hiyoshi Y, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Kazuyoshi Y, Mimori K, Baba H: PLOD2 as a potential regulator of peritoneal dissemination in gastric cancer. *Int J Cancer* (in press)
212. Yoshida N, Baba Y, Kuroda D, Miyamoto Y, Iwatsuki M, Hiyoshi Y, Ishimoto T, Sawayama H, Imamura Y, Watanabe M, Baba H: Clinical Utility of Exhaled Carbon Monoxide in Assessing Preoperative Smoking Status and Risks of Postoperative Morbidity after Esophagectomy. *Dis Esophagus* (in press)
213. Ohuchi M, Sakamoto Y, Tokunaga R, Kiyozumi Y, Nakamura K, Izumi D, Kosumi K, Harada K, Kurashige J, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Shono T, Naoe H, Sasaki Y, Baba H: Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer. *Oncol Lett* (in press)
214. Akagi J, Baba H, Sekine T, Ogawa K: Different CD57-related CD8+ T cell differentiation pathway are highly associated with the efficacy of immunotherapy using activated autologous lymphocytes. *Oncol Lett* (in press)
215. Akagi J, Baba H: CD57 ratio as a convenient and immunological and prognostic parameter for stage □ carcinoma. *Oncol Lett* (in press)
216. Yoshida N, Eto K, Baba Y, Hiyoshi Y, Watanabe M, Kurashige J, Iwagami S, Sakamoto Y, Miyamoto Y, Baba H: Short-term outcomes after esophagectomy for esophageal cancer patients with a history of gastrectomy. *Hepato-Gastroenterol* (in press)
217. Takeyama H, Hashimoto D, Ikeda K, Chikamoto A, Hayashi H, Beppu T, Suzuki M, Baba H: Comparison of KRAS status of resected lung metastasis and primary pancreatic cancer. *Hepato-Gastroenterol* (in press)
218. Beppu T, Hayashi H, Yoshida M, Nitta H, Imai K, Okabe H, Miyata T, Higashi T, Nakagawa S, Masuda T, Hashimoto D, Miyamoto Y, Chikamoto A, Ishiko T, Shiraishi S, Yamashita Y, Baba H: Preoperative chemotherapy on functional liver regeneration for colorectal liver metastases assessed with 99mTc-GSA SPECT/CT imaging. *Int Surg* (in press)
219. Ida S, Watanabe M: Conversion surgery for stage IV gastric cancer. *J Cancer Metastasis Treat* (in press)

麻酔科学分野

[研究プロジェクト名および概要]

- I. GPR103 及び GPR7 の侵害刺激伝達における役割
最近内因性のアゴニストが見つかった G タンパク共役型受容体である GPR103 と GPR7 はその存在部位から侵害刺激伝達に関与していることが想定されている。我々は、ラットを用いた *in vivo* の系で、GPR103 及び GPR7 の生体内での役割、特に侵害刺激伝達における役割を検討している。また、GPR103 の内因性作動物質である QRFP の knockout mouse を用いて、QRFP の生体内での侵害刺激伝達における役割を検討している。
- II. N-acetyl-aspartyl-glutamate (NAAG) の侵害刺激伝達における役割
NAAG は哺乳動物の中樞神経系に大量に存在する神経伝達物質である。しかし NAAG の役割は十分には解明されていない。我々は、NAAG 分解酵素阻害薬を用いて NAAG の侵害刺激伝達における役割を検討している。
- III. 神経障害性疼痛に対する各種薬物の効果について
現在神経障害性疼痛に対する治療薬としてガイドラインに示されている薬物は多く存在するが、どのような種類の痛みにも有用であるかについては十分には検討されていない。神経障害性疼痛モデルを用い、ガイドラインに示されているプレガバリン、デュロキセチン、モルヒネ、トラマドールの有効性の差を明らかにすることにより、臨床での各種薬物による神経障害性疼痛治療指針の作成を目指している。
- IV. 侵襲時におけるインスリン抵抗性と臓器障害 —分子生物学的アプローチ—
現在主にストレス惹起インスリン抵抗性血管内皮障害に対する Ras 阻害剤(ファルネシルトランスフェラーゼ阻害剤)の治療効果についての検討を行っている。血管内皮障害はインスリン抵抗性における重要臓器障害の主要因である。ターゲットとなるシグナルについては Nitrosative stress、PI-3kinase→eNOS 経路、NF- κ B を介した過剰な iNOS による NO 発生、Akt/PKB などがこれまで報告されてきた。一方 HMG-CoA 還元酵素阻害剤(スタチン)の lipid-lowering-independent effect がタンパクのファルネシル化抑制とされている。ファルネシルトランスフェラーゼ阻害剤で血管内皮障害を抑制できれば、さらにはスタチンの血管内皮障害治療への期待も広がることになる。重症患者モデルとして LPS マウスを用い、RAS 阻害剤である FTI-277 を腹腔内投与し、血管内皮障害への治療効果およびメカニズムについて、血管収縮弛緩反応、ウェスタンブロット法、免疫染色法にて解析を行っている。
- V. ペインクリニックにおける慢性疼痛患者と心理社会的要因 —心身医学的アプローチ—
従来からの薬物療法、神経ブロック治療に反応が乏しい慢性難治性疼痛患者に対して、心身医学的な評価と治療を行っている。生物学的モデルからみて、器質的病変は軽快・消失していると思われるのに、痛みを訴える患者をどうとらえればよいのであろうか。
もちろん鎮痛薬への反応性が悪いものの中には、神経障害性疼痛患者が含まれているので、鎮痛補助薬の使用が効果的であろう。それらを鑑別除外していくと、心理社会的背景の関与が問題となる。痛みという言葉で、患者が何を訴えているのかを理解することが解決の糸口となる。痛みに対する破局的思考、恐怖-回避モデル、抑うつ、心身症の中核概念であるアレキシサイミア(失感情症)、性格的な傾向としての強迫性、完璧主義、過剰適応、過活動(ペース配分の異常)、家族関係、虐待歴などから多面的に評価している。
- VI. 手術前には、誤嚥防止のため絶食・絶飲を行っている。しかしながら、どの程度の絶飲期間が必要であるかについては、定説がない。
そこで、絶食にしたボランティアに対して蒸留水・砂糖水・電解質液などを投与し、胃からの排泄時間を、エコーを用いて検討している。
- VII. 筋弛緩薬の効果とスガマデックスによる拮抗
肝機能低下の程度と筋弛緩薬の持続時間の相関を検討している。
年齢と筋弛緩薬持続時間との相関関係を検討
神経筋疾患患者における筋弛緩薬の効果持続時間
- VIII. 周術期の体温管理に関する研究
- IX. 麻酔器の基本的性能の検討、特に揮発性吸入麻酔薬の排出に関する研究

[教職員及び大学院学生]

教授 山本 達郎
講師 田代 雅文
講師 杉田 道子
講師 生田 義浩
助教 洲崎 祥子
助教 石村 達祐
助教 野中 崇広
大学院生 中村 真吾

[メールアドレス]

yamyam@kumamoto-u.ac.jp

[研究プロジェクト]

研究の総括
V
IV、VI
VIII、IX
IV
VIII、IX
I, II, III
I, II, III

[連絡先] 電話：096-373-5275 FAX：096-363-9697

[ホームページ] <http://kuma-ma.com>

【 英文論文 】

1. Miyazaki R, Yamamoto T (2012) Efficacy of morphine, pregabalin, gabapentin and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. *Anesth Analg* 115,182-188.
2. Sugita M, Harada H, Yamamoto T (2012) Operative management of a patient with thyroid hormone resistance who underwent total thyroidectomy for thyroid cancer. *J Anesth.* 26,595-597.
3. Yamada T, Zuo D, Yamamoto T, Olszewski RT, Bzdega T, Moffett JR, Neale JH (2012) NAAG Peptidase Inhibition in the Periaqueductal Gray and Rostral Ventromedial Medulla Reduces Flinching in the Formalin Model of Inflammation. *Mol Pain* 8, 67.
4. Fujimoto M, Tanahira C, Nishi M, Yamamoto T (2013) In non-obese patients, duration of action of rocuronium is directly correlated with body mass index. *Can J Anaesth* 60,552-556
5. Yamamoto T. (2014) When will we get a new class of analgesic agent based on animal study data. *J. Anesth.* 28:323-324.
6. Shinozaki T, Yamada T, Nonaka T, Yamamoto T (2015) Acetaminophen and non-steroidal anti-inflammatory drugs interact with morphine and tramadol analgesia for the treatment of neuropathic pain in rats. *J Anesth* 29, 386-395
7. Fujimoto M, Terasaki S, Nishi M, Yamamoto T (2015) Response to rocuronium and its determinants in patients with myasthenia gravis: A case-control study. *Eur J Anaesthesiol* 32,672-80
8. Nonaka T, Hara M, Miyamoto C, Sugita M, Yamamoto T (2016) Comparison of the analgesic effect of intravenous acetaminophen with that of flurbiprofen axetil on post-breast surgery pain: A randomized controlled trial. *J Anesth* 30, 405-409
9. Fukunaga C, Sugita M, Yamamoto T (2016) Validity of ultrasonographic measurement of gastric volume in fasted pediatric patients without sedation. *J Anesth* 30, 900-903
10. Nonaka T, Yamada T, Ishimura T, Zuo D, Moffett JR, Neale JH, Yamamoto T (2017) A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA. *Mol Pain* 13: 1-13 (DOI: 10.1177/1744806917697008)
11. Ono C, Sugita M, Ikuta Y, Yamamoto T (2017) Even low doses of dexmedetomidine produced obstructive apnea during spinal anesthesia. *Can J Anaesth* 64, 1289-1290
12. Fujimoto M, Kawano K, Yamamoto T (2017) The adequate rocuronium dose required for complete block of the adductor muscles of the thigh. *Acta Anaesth Scand* 62, 304-311

呼吸器外科学分野

【研究プロジェクト名および概要】

- I. 肺癌における DNA 異常メチル化の解析
- II. 胸部腫瘍に対する腫瘍内圧測定の意義
- III. 肺腺癌の発生にかかわる遺伝的素因の研究
- IV. 肺腺癌の発生、進行とエストロゲン代謝の関連の解析
- V. 呼吸器外科手術前後の低酸素血症の定量的評価

【教職員および大学院学生】

教授 鈴木 実
准教授 森 毅
講師 池田 公英
助教 白石 健治
助教 増田 佳子

大学院生 山田 竜也
大学院生 大隅 祥暢
大学院生 新地 祐介
医員 松原 恵理
医員 隈元 清仁
医員 松島 遼平

技術補佐員 吉田 彩香
事務補佐員 重藤 尚子

【メールアドレス】

smakoto@kumamoto-u.ac.jp
morimori@kumamoto-u.ac.jp
koei@cg7.so-net.ne.jp

【研究プロジェクト】

研究の統括
II
I, III, IV

I, III, IV

【連絡先】 電話: 096-373-5533 Fax: 096-373-5532

【ホームページ】 <http://kumadai-thoraic.com/>

【特殊技術・特殊装置】

1. 腫瘍内圧測定

【英文論文】

1. Novel approach to pleurodesis with 50 % glucose for air leakage after lung resection or pneumothorax.
Fujino K.*, Motooka Y., Koga T., Osumi H., Matsubara E., Shibata H., Ikeda K., Shiraishi K., Mori T., Hayashi K., Yoshimoto K., Wakimoto J., Kubota I., Suzuki M.
Surg Today 46, 599-602 (2016) [IF, 1.329; citation, 3]
2. Synchronous Multiple Lung Adenocarcinomas: Estrogen Concentration in Peripheral Lung.
Ikeda K.*, Shiraishi K., Yoshida A., Shinchi Y., Sanada M., Motooka Y., Fujino K., Mori T., Suzuki M.
PLoS One. 11 (2016) [IF, 3.057; citation, 0]
3. Chronic Progressive Pulmonary Aspergillosis after Surgry for Lung Cancer
Yamada T, Mori T, Nishi W, Motooka Y, Ikeda K, Shiraishi K, Suzuki M.
Kyobu Geka.2016Sep;69(10) Japanese.PubMed PMID:27586316.
4. Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.
Fujino K, Motooka Y, Hassan WA, Ali Abdalla MO, Sato Y, Kudoh S, Hasegawa K, Niimori-Kita K, Kobayashi H, Kubota I, Wakimoto J, Suzuki M, Ito T
Am J Pathol. 2015 Dec;185(12):3164-77.

5. Interstitial Fluid Pressure Correlates Clinicopathological Factors of Lung Cancer.
Mori T, Koga T, Shibata H, Ikeda K, Shiraishi K, Suzuki M, Iyama KI.
Ann Thorac Cardiovasc Surg. 2015 Jan 26
6. Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Matsubara E, Mori T, Koga T, Shibata H, Ikeda K, Shiraishi K, Suzuki M
Respir Med 2015
7. Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma.
Ikeda K.*, Shiraishi K., Koga T., Motooka Y., Fujino K., Shibata H., Mori T., Suzuki M
Ann Thorac Surg. 99, 1755-1759 (2015) [IF, 3.021; citation, 2]

【和文論文】

1. 左肺癌術直後の肺静脈断端内血栓による塞栓症の2例
古賀教将 森毅 柴田英克 池田公英 白石健治 鈴木実
日本呼吸器外科学会 30 卷 5 号 (2016)
2. ProGRP 高値を示した非定型肺カルチノイドの1例
山田竜也 吉本健太郎
日本臨床外科学会誌第 77 卷 6 号 (2016)

心臓血管外科学分野

【研究プロジェクト名および概要】

- I. 動脈硬化進展、動脈瘤形成に関する基礎的ならびに臨床的研究
 - I-1. 動脈硬化の発症・進展における分子機構の解析
 - I-2. 動脈瘤発生における分子機構の解析
- II. 虚血性心疾患の外科治療に関する臨床研究
 - II-1. びまん性冠動脈病変に対する外科的治療
 - II-2. 急性冠症候群に対する冠動脈バイパス術に関する多施設共同研究
- III. 日本の人工弁置換術後における抗血小板療法の有効性および安全性に関する研究
- IV. 高齢者大動脈弁狭窄症に対する経カテーテル大動脈弁置換術と外科的大動脈弁置換術の臨床的研究
- V. 動脈瘤に対するステントグラフトを用いた低侵襲手術の研究
 - V-1. 胸部大動脈瘤に対するステントグラフトを用いた血管内治療 (TEVAR)
 - V-2. 腹部大動脈瘤に対するステントグラフトを用いた血管内治療 (EVAR)
- VI. 新規組織工学を用いた、心臓血管外科領域の次世代型再生医療技術開発

【教職員および大学院生】

		メールアドレス
教授	福井 寿啓	(tmfukui@kumamoto-u.ac.jp)
助教	岡本 健	(okaken1967cmk@kuh.kumamoto-u.ac.jp)
助教	田爪 宏和	(tazume@kumamoto-u.ac.jp)
助教	野口 亮	(ryonoguchi0812@kumamoto-u.ac.jp)
特任助教	高木 淳	
非常勤講師	高橋 幸広	
非常勤講師	森山 周二	
非常勤講師	鈴木 龍介	
技術補佐員	谷口 裕子	
事務補佐員	船津 靖子	(shinzou@kumamoto-u.ac.jp)

【連絡先】 TEL:096-373-5205 FAX:096-373-5207 E-mail: shinzou@kumamoto-u.ac.jp

【ホームページ】 <http://kumamoto-cvs.com/>

【英文原著】

1. Nishigawa K, Fukui T, Yamazaki M, Takanashi S. Ten-year experience of coronary endarterectomy for the diffusely diseased left anterior descending artery. *Ann Thorac Surg.* 2017;103:710-716.
2. Sassa T, Okamoto K, Tazume H, Noguchi R, Koga A, Fukui T. Tricuspid valve repair with artificial chorda after previous ventricular septal repair. *Ann Thorac Surg.* 2017;103:e335-337.
3. Okamoto K, Tazume H, Koga A, Fukui T. Repair of left ventricular rupture in a patient with mitral annular calcification. *Interact Cardiovasc Thorac Surg.* 2017;24:972-973.
4. Usuku H, Kojima S, Kuyama N, Hanatani S, Araki S, Tshujita K, Tsunoda R, Fukui T, Hokimoto S. Multiple giant coronary artery aneurysms. *Intern Med.* 2017;56:1973-1976.
5. Nakanishi N, Ishii M, Kaikita K, Okamoto K, Izumiya Y, Yamamoto E, Takashio S, Hokimoto S, Fukui T, Tsujita K. When is the optimal timing of surgical intervention for severe functional tricuspid regurgitation? Case Report in *Cardiology.* 2017;2017:9232658.
6. Tazume H, Okamoto K, Fukui T. Concomitant aorto-right subclavian artery bypass with off-pump coronary artery bypass grafting: a case report. *J Cardiothorac Surg.* 2017.12:90.
7. Nishida H, Tabata M, Fukui T, Sato Y, Kin H, Takanashi S. A systematic approach to improve the outcomes of type A aortic dissection. *J Thorac Cardiovasc Surg.* 2017;154:89-96.
8. Nishigawa K, Fukui T, Takanashi S. Preoperative SYNTAX score to assess the late outcomes after coronary endarterectomy for the diffusely diseased left anterior descending artery. *Interact Cardiovasc Thorac Surg.* 2017;25:780-784
9. Kidoh M, Utsunomiya D, Funama Y, Ashikaga H, Nakaura T, Oda S, Yuki H, Hirata K, Iyama Y, Nagayama Y, Fukui T, Yamashita Y, Taguchi K. Vectors through a cross-sectional image (VCI): A visualization method for four-dimensional motion analysis for cardiac computed tomography. *J Cardiovasc Comput Tomogr.* 2017;11:468-473.
10. Fukui T. Management of acute aortic dissection and thoracic aortic rupture. *J Intensive Care.* 2017 (in press)
11. Koga A, Okamoto K, Tazume H, Fukui T. On-X prosthetic valve in a 42-year old female with antiphospholipid syndrome. *Heart Surg Forum.* 2017 (in press)
12. Nishida H, Fukui T, Kasegawa H, Kin H, Yamazaki M, Takanashi S. Causes of repair failure for degenerative mitral valve disease and reoperation outcomes. *Eur J Cardiothorac Surg.* 2018 (in press)

【和文総説】

1. 岡本健, 福井寿啓. 内臓動脈瘤. 日本臨床増刊号. 動脈・静脈の疾患 (下) 2017;75(Suppl5):811-814.
2. 福井寿啓. 冠動脈バイパス術の進歩. *Medicina.* 2017;54:1872-1875.

乳腺・内分泌外科学分野

【研究プロジェクト名および概要】

- I. 乳癌におけるエストロゲンレセプター(ER)の異常に関する研究
ER 遺伝子の増幅や変異と ER の機能特にホルモン依存性について検索する。
- II. エストロゲン療法における臨床的、基礎的検討
エストロゲン枯渇療法後の低用量エストロゲン療法の臨床的効果と基礎的メカニズムを検索する。
- III. Liquid Biopsy (採血検査) による治療効果予測診断
採血検体から得られる情報 (serum DNA, 全血 RNA, Exosome 中の核酸変異・発現) を解析し、次世代の治療効果診断ツールを創る。
- IV. 乳癌における Rare genomic aberration の臨床的意義の解明
近年の次世代シーケンスによって炙り出された乳癌の Rare genomic aberration が臨床的にどのような意義を持つのかを探り、治療への応用を検討する。
- V. 転移性乳癌におけるバイオロジーの解明
治療による淘汰や転移を起こすべきローンにより、転移巣は原発巣とは異なる性質を持つ。転移巣の腫瘍性質を解明し、臨床的重要性や治療への応用を検討する。
- VI. 臨床試験に附随した乳癌ホルモン療法に関するトランスレーショナル研究
非ステロイド系アロマターゼ阻害薬に不応例に対する治療法の模索、また手術前に短期間ホルモン療法を施行した際の腫瘍性質の変化を捉えることで非ステロイド系アロマターゼ阻害薬による治療効果予測を、オリジナルの臨床試験と連動して包括的に行う。
- VII. BRCA1 機能低下と Triple Negative 乳癌に関する研究
原発・転移乳癌を対象に BRCA1 機能低下による遺伝子修復機構不全について検索し、治療効果予測診断を行う。
- VIII. 全身治療に先立つセンチネルリンパ生検による新しい乳癌治療の組み立てに関する研究
SNB の実臨床的な研究とリンパ節微小転移の臨床的意義について検討する。

【教職員および大学院学生】

【メールアドレス】

【研究プロジェクト】

教授	岩瀬 弘敬	hiwase@kumamoto-u.ac.jp	研究の統括
准教授	山本 豊	ys-yama@triton.ocn.ne.jp	I, II, III, IV, V, VI, VII, VIII
特任准教授	指宿 睦子	mibusuki@kumamoto-u.ac.jp	I, II, III, IV, V, VI, VII, VIII
助教	末田 愛子		III, IV, V, VI, VII, VIII
助教	竹下 卓志		I, II, III, IV, V, VIII
特任助教	富口 麻衣		III, IV, V, VI, VII, VIII
医員	藤木 義敬		IV, V, VII
大学院生 (博士課程)	後藤 理沙		IV, V, VII
専攻医	藤川 和晃		IV, V, VII
大学院生 (博士課程)	邱 什		IV, V, VII

【連絡先】 電話: 096-373-5521 Fax: 096-373-5525

【ホームページ】 <http://www2.kuh.kumamoto-u.ac.jp/breast/index.html>

【特殊技術・特殊装置】

1. センチネルリンパ節生検
2. Vacuum Assisted Biopsy
3. 免疫組織化学法
4. Digital PCR, 定量 PCR による変異発現解析
5. 統計学的解析手法
6. DNA シークエンス解析
7. FISH 法による遺伝子増幅解析
8. 家族性腫瘍の遺伝子検索

【英文論文】

1. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Sueta A, Tomiguchi M, Murakami K, Iwase H.: Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients *BMC Cancer*. 17(1):786, 2017.
2. Sueta A, Yamamoto Y, Tomiguchi M, Takeshita T, Yamamoto-Ibusuki M, Iwase H.: Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence. *Oncotarget*. 8(41):69934-69944,2017
3. Guo J, Sueta A, Nakamura K, Yoshimoto N, Baba M, Ishida N, Hagio K, Toyama T, Iwase H, Tamakoshi A, Yamashita H.: Genetic and environmental factors and serum hormones, and risk of ER-positive breast cancer in pre- and postmenopausal Japanese women. *Oncotarget*. 8(39):65759-65769,2017
4. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Omoto Y, Iwase H. Analysis of *ESR1* and *PIK3CA* mutations in plasma cell-free DNA from ER-positive breast cancer patients. *Oncotarget*. 8(32):52142-52155,2017
5. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Omoto Y, Iwase H: Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients. *Transl Oncol* 10(5):766-771,2017.
6. Suyama K, Fujiwara S, Takeshita T, Sueta A, Inao T, Yamamoto-Ibusuki M, Yamamoto Y, Iwase H. Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer. *Mol Clin Oncol*. 7(1):24-26,2017.
7. Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. *Invest New Drugs*. 35(6):791-799,2017
8. Kawase K, Nomura K, Tominaga R, Iwase H, Ogawa T, Shibasaki I, Shimada M, Taguchi T, Takeshita E, Tomizawa Y, Nomura S, Hanazaki K, Hanashi T, Yamashita H, Kokudo N, Maeda K. Analysis of gender-based differences among surgeons in Japan: results of a survey conducted by the Japan Surgical Society. Part 1: Working style. *Surg Today* 48(1):33-43,2017.
9. Miyasato Y, Shiota T, Ohnishi K, Pan C, Yano H, Horlad H, Yamamoto Y, Yamamoto-Ibusuki M, Iwase H, Takeya M, Komohara Y. High density of CD204-positive macrophages predicts worse clinical prognosis in patients with breast cancer. *Cancer Sci*. 108(8):1693-1700,2017.
10. Sueta D, Suyama K, Sueta A, Tabata N, Yamashita T, Tomiguchi M, Takeshita T, Yamamoto-Ibusuki M, Yamamoto E, Izumiya Y, Kaikita K, Yamamoto Y, Hokimoto S, Iwase H, Tsujita K. Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. *Atherosclerosis*. 260:116-120,2017.
11. Tomita S, Abdalla MO, Fujiwara S, Yamamoto T, Iwase H, Nakao M, Saitoh N. Roles of long noncoding RNAs in chromosome domains. *Wiley Interdiscip Rev RNA*. 2017 Mar; 8(2). doi: 10.1002/wrna.1384. Epub 2016 Aug 3. Review.
12. Kawaguchi H, , Yamamoto Y, Ohno S, Toi M. et al.: Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari). *Breast Cancer Res Treat*. 163(3):545-554, 2017
13. Iwata H, Masuda N, Yamamoto D, Sagara Y, Sato N, Yamamoto Y, Saito M, Fujita T, Oura S, Watanabe J, Tsukabe M, Horiguchi K, Hattori S, Matsuura Y, Kuroi K. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. *Breast Cancer Res Treat*. 162(3):501-510, 2017

【和文原著・総説】

1. 竹下卓志, 岩瀬弘敬 転移乳癌におけるリキッドバイオプシーの診断技術 PHARMSTAGE 1-7 2017年12月
2. 岩瀬弘敬, .総論 乳癌診療の歴史、現況と将来展望 日本臨牀 増刊号 乳癌学 最新の診断と治療 日本臨牀社 75巻増刊号3 (通巻1119号) 5-9 2017年4月
3. 山本 豊, .乳癌の治療 乳癌の薬物療法と支持療法 乳癌の抗HER2療法 転移・再発乳癌の抗HER2療法 日本臨牀 増刊号 乳癌学 最新の診断と治療 日本臨牀社 75巻増刊号3 (通巻1119号) 342-350 2017年4月

脳神経外科学分野

【研究プロジェクト名および概要】

- I. 脳腫瘍の病態と治療に関する研究
 1. グリオーマの病態解析と新規治療法の開発
 2. 悪性脳腫瘍（悪性リンパ腫、悪性髄膜腫など）の分子生物学的特性の解明
 3. 脳腫瘍の疫学
- II. 脳血管障害疾患の病態と治療に関する研究
 1. 脳卒中（脳虚血や脳出血）における神経細胞死のメカニズムとその治療法の開発
 2. 血管内治療における塞栓物質とその治療法の開発
 3. 脳血管障害の疫学
- III. 大脳基底核疾患の病態の解明と治療に関する研究
 1. 大脳基底核神経回路網形成機構の解明
 2. 脳深部刺激装置を用いた大脳基底核疾患の治療
- IV. 視床下部・脳下垂体疾患の病態と治療に関する研究
 1. 機能性下垂体腺腫におけるホルモン産生メカニズムの解明と治療法の開発
 2. 嚢胞性疾患における嚢胞形成機序の解明と根治的治療法の開発
 3. 間脳・下垂体部腫瘍の疫学
- V. てんかん脳の病態・機能解析

【教職員および大学院学生】	【メールアドレス】	【研究プロジェクト】
教授 武笠 晃丈	(mukasa@kumamoto-u.ac.jp)	研究統括、I、
准教授 矢野 茂敏	(yanos@kumamoto-u.ac.jp)	I, IV
特任教授 山田 和慶	(yamadakazu@kuh.kumamoto-u.ac.jp)	III
講師 牧野 敬史	(kmakino@kuh.kumamoto-u.ac.jp)	I
助教 河野 隆幸	(tkawano-nsu@umin.ac.jp)	II
助教 浜崎 禎	(thamasaki-nsu@umin.ac.jp)	III, V
助教 篠島 直樹	(nshinojima@kuh.kumamoto-u.ac.jp)	I, IV
特任助教 大森 雄樹	(ohmori4497@gmail.com)	II
助教 黒田 順一郎	(jukuroda@kumamoto-u.ac.jp)	I
助教 天達 俊博	(toshihiroa@kuh.kumamoto-u.ac.jp)	II
大学院生 賀来 藍子	(博士課程 4年)	I
大学院生 山本 隆広	(博士課程 4年)	I
大学院生 藤本 健二	(博士課程 4年)	I
大学院生 岳元 裕臣	(博士課程 3年)	II
大学院生 林 建佑	(博士課程 3年)	II
大学院生 甲斐 恵太郎	(博士課程 1年)	I
大学院生 内川 裕貴	(博士課程 1年)	II

【連絡先】 Tel: 096-373-5219 Fax: 096-371-8064

【ホームページ】 <http://www2.kuh.kumamoto-u.ac.jp/neurosurgery/>

【特殊技術・特殊装置】

1. 細胞培養
クリーンベンチ、CO2 インキュベーターなど
2. 神経細胞初代培養
3. 脳組織スライス器官培養
4. 遺伝子工学機器
DNA-sequencer, DNA-thermal cycler, PCR など
5. 位相差顕微鏡、共焦点レーザー顕微鏡
6. 組織解析法全般
一般染色、免疫染色、蛍光染色
7. 動物実験機器
脳血流計、定位脳手術装置、血圧計、血管撮影装置、麻酔装置など
8. 生化学研究機器

- 遠心機、恒温槽、Western Blot 用機器など
9. 手術用ナビゲーション装置
 10. 定位脳手術装置
 11. 神経電気生理記録装置
 12. 手術用内視鏡装置
紫色半導体レーザー装置（術中蛍光診断装置）

【英文原著】

1. Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T, Nagata Y, Yoshizato T, Mizoguchi M, Abe T, Momii Y, Muragaki Y, Watanabe R, Ito I, Sanada M, Yajima H, Morita N, Takeuchi I, Miyano S, Wakabayashi T, Ogawa S, Natsume A: Prognostic relevance of genetic alterations in diffuse lower-grade gliomas, *Neuro-oncology* 2018, 20:66-77
2. Hamasaki T, Yano S, Nakamura K, Yamada K: Pregabalin as a salvage preoperative treatment for refractory trigeminal neuralgia, *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia* 2018, 47:240-244
3. Hayashi K, Makino K, Nakagawa T, Yano S: Spontaneous Repeated Disappearance and Recurrence of Multiple Spinal Intradural Arachnoid Cysts in a Child, *World neurosurgery* 2018, 111:358-360
4. Hide T, Komohara Y, Miyasato Y, Nakamura H, Makino K, Takeya M, Kuratsu JI, Mukasa A, Yano S: Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border, *EBioMedicine* 2018, Mar 1. pii: S2352-3964(18)30083-5. doi: 10.1016/j.ebiom.2018.02.024. [Epub ahead of print]
5. Komuro A, Raja E, Iwata C, Soda M, Isogaya K, Yuki K, Ino Y, Morikawa M, Todo T, Aburatani H, Suzuki H, Ranjit M, Natsume A, Mukasa A, Saito N, Okada H, Mano H, Miyazono K, Koinuma D: Identification of a novel fusion gene HMGA2-EGFR in glioblastoma, *International journal of cancer* 2018, 142:1627-1639
6. Wakabayashi T, Natsume A, Mizusawa J, Katayama H, Fukuda H, Sumi M, Nishikawa R, Narita Y, Muragaki Y, Maruyama T, Ito T, Beppu T, Nakamura H, Kayama T, Sato S, Nagane M, Mishima K, Nakasu Y, Kurisu K, Yamasaki F, Sugiyama K, Onishi T, Iwadate Y, Terasaki M, Kobayashi H, Matsumura A, Ishikawa E, Sasaki H, Mukasa A, Matsuo T, Hirano H, Kumabe T, Shinoura N, Hashimoto N, Aoki T, Asai A, Abe T, Yoshino A, Arakawa Y, Asano K, Yoshimoto K, Shibui S, Members of Japan Clinical Oncology Group Brain Tumor Study G: JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonbeta plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma, *Journal of neuro-oncology* 2018, Mar 20. doi: 10.1007/s11060-018-2831-7. [Epub ahead of print]
7. Yamamoto T, Hamasaki T, Nakamura H, Yamada K: Improvement of visual field defects after focal resection for occipital lobe epilepsy: case report, *Journal of neurosurgery* 2018, 128:862-866
8. Yano S, Shinojima N, Kitajima M, Uetani H, Hide T, Mukasa A: Usefulness of Oblique Coronal Computed Tomography and Magnetic Resonance Imaging in the Endoscopic Endonasal Approach to Treat Skull Base Lesions, *World neurosurgery* 2018, Jan 8. pii: S1878-8750(18)30062-7. doi: 10.1016/j.wneu.2018.01.022. [Epub ahead of print]
9. Makino K, Hirai T, Nakamura H, Kuroda JI, Shinojima N, Uetani H, Kitajima M, Yano S: Differentiating Between Primary Central Nervous System Lymphomas and Glioblastomas: Combined Use of Perfusion-Weighted and Diffusion-Weighted Magnetic Resonance Imaging, *World neurosurgery* 2018, 112:e1-e6
10. Shinojima N, Fujimoto K, Makino K, Todaka K, Yamada K, Mikami Y, Oda K, Nakamura K, Jono H, Kuratsu JI, Nakamura H, Yano S, Mukasa A: Clinical significance of polyglutamylation in primary central nervous system lymphoma, *Acta neuropathologica communications* 2018, 6:15
11. Thomas JG, Parker Kerrigan BC, Hossain A, Gumin J, Shinojima N, Nwajei F, Ezhilarasan R, Love P, Sulman EP, Lang FF: Ionizing radiation augments glioma tropism of mesenchymal stem cells, *Journal of neurosurgery* 2018, 128:287-295
12. Aihara K, Mukasa A, Nagae G, Nomura M, Yamamoto S, Ueda H, Tatsuno K, Shibahara J, Takahashi M, Momose T, Tanaka S, Takayanagi S, Yanagisawa S, Nejo T, Takahashi S, Omata M, Otani R, Saito K, Narita Y, Nagane M, Nishikawa R, Ueki K, Aburatani H, Saito N: Genetic and epigenetic stability of oligodendrogliomas at recurrence, *Acta neuropathologica communications* 2017, 5:18
13. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Contier C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, Lopez-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liao LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpena-Diazconti M, Chico Ponce de Leon F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD: Intertumoral Heterogeneity within Medulloblastoma Subgroups, *Cancer cell* 2017, 31:737-754 e736
14. Fujimoto K, Yano S, Shinojima N, Hide T, Kuratsu JI: Endoscopic endonasal transsphenoidal surgery for patients aged over 80 years with pituitary adenomas: Surgical and follow-up results, *Surgical neurology international* 2017, 8:213
15. Fukushima S, Yamashita S, Kobayashi H, Takami H, Fukuoka K, Nakamura T, Yamasaki K, Matsushita Y, Nakamura H, Totoki Y, Kato M, Suzuki T, Mishima K, Yanagisawa T, Mukasa A, Saito N, Kanamori M, Kumabe T, Tominaga T, Nagane M, Iuchi T, Yoshimoto K, Mizoguchi M, Tamura K, Sakai K, Sugiyama K, Nakada M, Yokogami K, Takeshima

- H, Kanemura Y, Matsuda M, Matsumura A, Kurozumi K, Ueki K, Nonaka M, Asai A, Kawahara N, Hirose Y, Takayama T, Nakazato Y, Narita Y, Shibata T, Matsutani M, Ushijima T, Nishikawa R, Ichimura K, Intracranial Germ Cell Tumor Genome Analysis C: Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas, *Acta neuropathologica* 2017, 133:445-462
16. Hasegawa H, Shin M, Kondo K, Hanakita S, Mukasa A, Kin T, Saito N: Role of endoscopic transnasal surgery for skull base chondrosarcoma: a retrospective analysis of 19 cases at a single institution, *Journal of Neurosurgery* 2017, 1-10
 17. Hayashi N, Takahashi H, Hasegawa Y, Higuchi F, Takahashi M, Makino K, Takagaki M, Akimoto J, Okuda T, Okita Y, Mitsuya K, Hirashima Y, Narita Y, Nakasu Y, Committee of Brain Tumor Registry of Japan Supported by the Japan Neurosurgical S: A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer, *BMC cancer* 2017, 17:397
 18. Kadota Y, Hirai T, Nakamura H, Makino K, Yano S, Nishimura S, Tateishi M, Azuma M, Kitajima M, Yamashita Y: Benefit of 3T Diffusion-weighted Imaging in Comparison to Contrast-enhanced MR Imaging for the Evaluation of Disseminated Lesions in Primary Malignant Brain Tumors, *Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine* 2017, 16:217-222
 19. Kaku Y, Ohmori Y, Kawano T, Takeshima Y, Kuratsu JI: Remote Lesions of Synchronous Sacral and Cervical Dural Arteriovenous Fistulas: A Case Report, *World neurosurgery* 2017, 105:1037 e1013-1037 e1016
 20. Miura M, Nakajima M, Fujimoto A, Kaku Y, Kawano T, Watanabe M, Kuratsu JI, Ando Y: High prevalence of small vessel disease long after cranial irradiation, *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia* 2017, 46:129-135
 21. Mukasa A, Yanagisawa S, Saito K, Tanaka S, Takai K, Shibahara J, Ikegami M, Nakao Y, Takeshita K, Matsutani M, Saito N: Successful treatment of mixed yolk sac tumor and mature teratoma in the spinal cord: case report, *Journal of neurosurgery Spine* 2017, 26:319-324
 22. Nakajima N, Nobusawa S, Nakata S, Nakada M, Yamazaki T, Matsumura N, Harada K, Matsuda H, Funata N, Nagai S, Nakamura H, Sasaki A, Akimoto J, Hirato J, Yokoo H: BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity, *Brain pathology* 2017, Nov 4. doi: 10.1111/bpa.12572. [Epub ahead of print]
 23. Nakamura T, Yamashita S, Fukumura K, Nakabayashi J, Tanaka K, Tamura K, Tateishi K, Kinoshita M, Fukushima S, Takami H, Fukuoka K, Yamazaki K, Matsushita Y, Ohno M, Miyakita Y, Shibui S, Kubo A, Shuto T, Kocalkowski S, Yamanaka S, Mukasa A, Sasayama T, Mishima K, Maehara T, Kawahara N, Nagane M, Narita Y, Mano H, Ushijima T, Ichimura K: Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma, *Acta neuropathologica* 2017, 133:321-324
 24. Nomura M, Mukasa A, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Suzuki T, Otani R, Kobayashi K, Maruyama T, Tanaka S, Takayanagi S, Nejo T, Takahashi S, Ichimura K, Nakamura T, Muragaki Y, Narita Y, Nagane M, Ueki K, Nishikawa R, Shibahara J, Aburatani H, Saito N: Distinct molecular profile of diffuse cerebellar gliomas, *Acta neuropathologica* 2017, 134:941-956
 25. Otani R, Mukasa A, Shin M, Omata M, Takayanagi S, Tanaka S, Ueki K, Saito N: Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma, *Journal of neurosurgery* 2017, 1-10
 26. Takahashi M, Soma T, Mukasa A, Koyama K, Arai T, Momose T: An automated voxel-based method for calculating the reference value for a brain tumour metabolic index using (18)F-FDG-PET and (11)C-methionine PET, *Annals of nuclear medicine* 2017, 31:250-259
 27. Takahashi Y, Sawada T, Akahane T, Kawase Y, Ikeda H, Makino K, Nakamura H, Hide T, Yano S, Hashimoto N, Kamada H: Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma, *Oncology letters* 2017, 14:264-270
 28. Takai K, Tanaka S, Sota T, Mukasa A, Komori T, Taniguchi M: Spinal Cord Astrocytoma with Isocitrate Dehydrogenase 1 Gene Mutation, *World neurosurgery* 2017, 108:991 e913-991 e916
 29. Takashima H, Tsuji AB, Saga T, Yasunaga M, Koga Y, Kuroda JI, Yano S, Kuratsu JI, Matsumura Y: Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model, *Scientific reports* 2017, 7:12341
 30. Takayanagi S, Mukasa A, Nakatomi H, Kanno H, Kuratsu JI, Nishikawa R, Mishima K, Natsume A, Wakabayashi T, Houkin K, Terasaka S, Yao M, Shinohara N, Shuin T, Saito N: Development of Database and Genomic Medicine for von Hippel-Lindau Disease in Japan, *Neurologia medico-chirurgica* 2017, 57:59-65
 31. Takayanagi S, Mukasa A, Tanaka S, Nomura M, Omata M, Yanagisawa S, Yamamoto S, Ichimura K, Nakatomi H, Ueki K, Aburatani H, Saito N: Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system, *Neuro-oncology* 2017, 19:1228-1236
 32. Takeshima Y, Ohmori Y, Nakagawa T, Kaku Y, Kuratsu JI, Yano S: Subarachnoid Hemorrhage Because of Distal Superior Cerebellar Artery Dissection in Neurofibromatosis Type 1, *World neurosurgery* 2017, 105:1036 e1015-1036 e1019
 33. Uchikawa H, Nishi T, Kaku Y, Goto T, Kuratsu JI, Yano S: Delayed Development of Aneurysms Following Gamma Knife Surgery for Trigeminal Neuralgia: Report of 2 Cases, *World neurosurgery* 2017, 99:813 e813-813 e819
 34. Uetani H, Hirai T, Kitajima M, Azuma M, Yano S, Nakamura H, Makino K, Kai Y, Nagayama Y, Kadota Y, Yamashita Y: Additive Value of 3T 3D CISS Imaging to Conventional MRI for Assessing the Abnormal Vessels of Spinal Dural Arteriovenous Fistulae, *Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of*

Magnetic Resonance in Medicine 2017, Nov 29. doi: 10.2463/mrms.mp.2016-0098. [Epub ahead of print]

35. Yano S, Hide T, Shinojima N: In Reply to "Craniopharyngioma: Surgical Outcome as Related to the Degree of Hypothalamic Involvement", *World neurosurgery* 2017, 104:1011-1013
36. Yano S, Hide T, Shinojima N: Surgical Outcomes of Endoscopic Endonasal Skull Base Surgery of Craniopharyngiomas Evaluated According to the Degree of Hypothalamic Extension, *World neurosurgery* 2017, 100:288-296
37. Yano S, Hide T, Shinojima N: Efficacy and Complications of Endoscopic Skull Base Surgery for Giant Pituitary Adenomas, *World neurosurgery* 2017, 99:533-542
38. Yano S, Shinojima N, Kawashima J, Kondo T, Hide T: Intraoperative Scoring System to Predict Postoperative Remission in Endoscopic Endonasal Transsphenoidal Surgery for Growth Hormone-Secreting Pituitary Adenomas, *World neurosurgery* 2017, 105:375-385

【和文論文】

1. 山田和慶、篠島直樹、浜崎 禎:
パーキンソン病・不随意運動症に対する DBS のアップデートと将来展望
脳神経外科ジャーナル 26: 873-881, 2017
2. 山田和慶、篠島直樹、浜崎 禎:
パーキンソン病・不随意運動症に対する DBS
-false-negative indication の回避を目指して-
脳神経外科ジャーナル 26: 280-286, 2017
3. 山田和慶:
機能神経外科による認知症治療への期待
日本早期認知症学会誌 第 10 巻 第 1 号: 13-25, 2017
4. 山田和慶、篠島直樹、浜崎 禎:
二次性半身ジストニアに対する淡蒼球内節刺激術の意義
機能的神経外科 56: 23-30, 2017
5. 牧野敬史、黒田順一郎、中村英夫、矢野茂敏:
小児水頭症患者に対するシャント術後の長期フォローアップの必要性についての検討
小児の脳神経 42: 350-354, 2017

整形外科学分野

【研究プロジェクト名および概要】

1. 軟骨変性の分子メカニズムに関する研究
2. 人工膝関節の生体内運動解析に関する研究
3. MRI を用いた軟骨代謝の画像評価に関する研究
4. 日本人に特化した人工股関節の開発と臨床応用に関する研究
5. 増殖分化シグナルによる肩腱板の修復制御機構とその臨床応用に関する研究
6. 骨・軟部腫瘍における MRI 拡散強調画像の応用に関する研究
7. 新たな腫瘍マーカーの開発と臨床応用に関する研究
8. 脊髄機能評価への MRI の応用に関する研究
9. 脊柱管狭窄症における黄色靭帯肥厚の分子メカニズムに関する研究

【教職員および大学院学生】

【メールアドレス】

【研究プロジェクト】

教授

講師 中村 英一 h@kumamoto-u.ac.jp 2. 3.

藤本 徹 torufuji@kuh.kumamoto-u.ac.jp 8. 9.

唐杉 樹 tatsukik@kuh.kumamoto-u.ac.jp 1. 5.

助教 谷脇 琢也 takuyataniwaki@kuh.kumamoto-u.ac.jp 8. 9.

岡元 信和 nobuoka9999@kuh.kumamoto-u.ac.jp 1. 2.

佐藤 広生 hiro-sato@kuh.kumamoto-u.ac.jp 6. 7.

岡 潔 okakiyo@kuh.kumamoto-u.ac.jp 4. 6.

特任助教 末吉 貴直 sueyoshi@kuh.kumamoto-u.ac.jp 6. 7.

岡田 龍哉 tatsuyaokada@kuh.kumamoto-u.ac.jp 8. 9.

大学院博士課程 杉本 一樹 kazuki1187@kuh.kumamoto-u.ac.jp 9.

米満 龍史 r-yonemitsu@kuh.kumamoto-u.ac.jp 5.

井手尾勝政 kacofkac@kuh.kumamoto-u.ac.jp 5.

松下 紘三 kozo.kozo.0602@gmail.com

【連絡先】 Tel : 096-373-5226 Fax : 096-373-5228

E-mail : seikeigeka@kumamoto-u.ac.jp

【ホームページ】 <http://kumadai-seikei.com>

【特殊技術・特殊装置】

1. 筋力測定装置 (Cybex-340)
2. 神経伝導機能検査装置
3. レーザードップラー血流波形分析装置
4. 関節弛緩測定装置 (KT-1000 arthrometer、Stryker knee laxity tester)
5. 核酸解析装置
6. 蛋白解析装置
7. 細胞培養装置

【英文論文】

1. Tsukamoto H, Fujieda K, Hirayama M, Yunoo A, Ikeda T, Matsumura K, Fukuma D, Araki K, Mizuta H, Nakayama H, Senju S, and Nishimura, Y. Soluble IL-6R expressed by myeloid cells reduces tumor-specific Th1 differentiation and drives tumor progression. (*equally contributed author) *Cancer Research* 77(9):2279-2291, 2017.
2. Arimura H, Shukunami C, Tokunaga T, Karasugi T, Okamoto N, Taniwaki T, Sakamoto H, Mizuta H, Hiraki Y. TGF- β 1 improves the biomechanical strength by extracellular matrix accumulation without increasing the number of tenogenic lineage cells in a rat rotator cuff repair model. *American Journal of Sports Medicine* 45(10):2394-2404, 2017.
3. Tokunaga T, Karasugi T, Arimura H, Yonemitsu R, Sakamoto H, Ide J, Mizuta H. Enhancement of rotator cuff tendon-bone healing with FGF-2 impregnated in gelatin hydrogel sheets in a rabbit model. *Journal of Shoulder and Elbow Surgery* 26(10):1708-1717, 2017.
4. Kukidome D, Nishikawa T, Sato M, Nishi Y, Shimamura R, Kawashima J, Shimoda S, Mizuta H, Araki E. Impaired balance is related to the progression of diabetic complications in both young and older adults. *Journal of diabetes and its complications* 31(8):1275-1282, 2017.
5. Miyake M, Kuroda M, Kiyonari H, Takehana K, Hisanaga S, Morimoto M, Zhang J, Oyadomari M, Sakaue H, Oyadomari S. Ligand-induced rapid skeletal muscle atrophy in HSA-Fv2E-PERK transgenic mice. *PLoS One*. 12(6):e0179955, 2017.
6. Ide J, Mochizuki Y, Arthur van Noort, Ochi H, Sridharan S, Itoi E, Greiner S. Local rhBMP-12 on an absorbable collagen sponge as adjuvant therapy for rotator cuff repair: A phase 1, randomized, standard of care control, multicenter study. Part 2: A pilot study of functional recovery and structural outcome. *Orthopaedic Journal of Sports Medicine* 5(9):2325967117726740, 2017. Online.
7. Onodera J, Yasuda K, Masuda T, Tanabe Y, Kitamura N, Yagi T, Kondo E. Is the grafted tendon shifted anteriorly in the femoral tunnel at the post-remodeling phase after anterior cruciate ligament reconstruction? A clinical MRI study. *Orthopaedic Journal of Sports Medicine* 5(6): 2325967117711120, 2017. Online.
8. Hirose J, Nagata T, Ogushi M, Okamoto N, Taniwaki T, Oka K, Tomiguchi W, Koga H, Hayashi K, Usuku K, Mizuta H. Validation of each category of Kihon Checklist for assessing physical functioning, nutrition, and cognitive status in a community-dwelling older Japanese cohort. *Epidemiology* 7(5): 1-15, 2017.
9. Nakamura E, Nishioka H, Okamoto N, Yamabe S, Masuda T, Shiraishi D, Mizuta H. Articular Cartilage Changes in MRI T1-rho and T2 Mapping in an Open-Wedge Osteotomy of the Proximal Tibia with Hemicallotaxis for the Medial Knee Osteoarthritis. *Arthroscopy*. 33(10): e110–e111, 2017.
10. Nakamura E. Importance of a Dynamic Evaluation of Tibial Osteotomy for Medial Knee Osteoarthritis. *Clinics in Surgery*. Article 1832, E Pub: 20 Dec, 2017.
11. Korogi W, Yoshizawa T, Karim Md, Tanoue H, Yugami M, Sobuz SU, Hinoi E, Sato Y, Oike Y, Mizuta H, Yamagata K. SIRT7 is an important regulator of cartilage homeostasis and osteoarthritis development. *Biochemical and Biophysical Research Communications* 496 (3): 891-897, 2018.
12. Hisanaga S, Miyake M, Taniuchi S, Oyadomari M, Morimoto M, Sato R, Hirose J, Mizuta H, Oyadomari S. PERK-mediated translational control is required for collagen secretion in chondrocytes. *Scientific reports*. 8(1):773, 2018.
13. Tanoue H, Morinaga J, Yoshizawa T, Yugami M, Ito H, Nakamura T, Uehara Y, Masuda T, Odagiri H, Sugisaki T, Kadomatsu T, Miyata A, Endo M, Terada K, Ochi H, Takeda S, Fukuda K, Yamagata K, Mizuta H, Oike Y. Angiopoietin-like protein 2 promotes chondrogenic differentiation during bone growth as a cartilage matrix factor. *Osteoarthritis and Cartilage* 26(1):108-117, 2018.
14. Sueta D, Kaikita K, Okamoto N, Yamabe S, Ishii M, Arima Y, Ito M, Oimatsu Yu, Mitsuse T, Iwashita S, Nakamura E, Hokimoto S, Mizuta H, Ogawa H, Tsujita K. Edoxaban Enhances Thromboprophylaxis by Physiotherapy After Total Knee Arthroplasty -The Randomized Controlled ESCORT-TKA Trial-. *Circulation Journal* 82(2):524-531, 2018.
15. Ide J, Tokunaga T. Rotator cuff tendon-to-bone healing at 12 months after patch grafting of acellular dermal matrix in an animal model. *Journal of Orthopaedic Science* 23(2):207-212, 2018.
16. Itoh H, Kadomatsu T, Tanoue H, Yugami M, Miyata K, Endo M, Morinaga J, Kobayashi E, Miyamoto T, Kurahashi R, Terada K, Mizuta H, Oike Y. TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma. *ONCOGENE*. (in press)
17. Shiraishi D, Fujiwara Y, Horlad H, Saito Y, Iriki T, Tsuboki J, Cheng P, Nakagata N, Mizuta H, Bekki H, Nakashima Y, Oda Y, Takeya M, Komohara Y. CD163 is involved in the protumour activation of macrophages in human and murine sarcoma. *Cancer Research*. (in press)

泌尿器科学分野

【研究プロジェクト名および概要】

- I. 腎細胞癌に対する分子標的療法の感受性および抵抗性に関する研究
- II. 転座型腎細胞癌の発生・進展に関わる分子機構に関する研究
- III. 泌尿器科悪性腫瘍の発生・進展におけるマクロファージの役割に関する研究
- IV. 泌尿器科悪性腫瘍におけるアナフィラトキシン C5a とそのレセプターシステムに関する研究
- V. 3D 培養を用いた泌尿器科悪性腫瘍における新規標的分子探索に関する研究
- VI. 癌微小環境で免疫抑制に係る分子機構の解明に関する研究
- VII. 泌尿器疾患に対する治療成績に関するアウトカム研究
- VIII. 泌尿器科疾患に対する鏡視下手術・ロボット手術に関する研究
- IX. 尿路平滑筋機能および排尿機能、病態に関する研究

	【教職員および大学院学生】	【メールアドレス】	【研究プロジェクト】
教授	神波 大己	kamba@kumamoto-u.ac.jp	研究の統括
病院講師	山口 隆大		VII, VIII
助 教	田上 憲一郎		VI, VIII
助 教	杉山 豊		VI, VIII, IX
助 教	矢津田 旬二		III, IV, VII, VIII
助 教	村上 洋嗣		III, IV, VII, VIII
助 教	元島 崇信		I, II, III, V, VI, VII
特任助教	福島 結美		VII, VIII, IX
医 員	黒川 慎一郎		VII, VIII, IX
大学院生	倉橋 竜磨		I, II
大学院生	今村 隆二		III, IV
大学院生	上園 英太		II, V, VI
大学院生	原 千瑛		I, II, VI
事務補佐員	坂田 朋美		
事務補佐員	吉見 有加		

【連絡先】 電話：096-373-5241 Fax：096-373-5242

【ホームページ】 <https://kumamoto-urology.com>

【英文論文】

1. Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M, Eto M. Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells. **Oncol Rep.** 33(6), 2947-53, 2015.
2. Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, Kikuchi K, Imamura T, Eto M. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. **Oncol Rep.** 33(4), 1844-50, 2015.
3. Saito Y, Ohnishi K, Miyashita A, Nakahara S, Fujiwara Y, Horlad H, Motoshima T, Fukushima S, Jinnin M, Ihn H, Takeya M, Komohara Y. Clinicopathological and prognostic significance of CD169+ lymph node sinus macrophages in patients with malignant melanoma. **Cancer Immunol Res.** 3(12), 1356-63, 2015.
4. Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M. CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma. **Oncol Lett.** 11(3), 1911-1916, 2016.
5. Ma C, Komohara Y, Ohnishi K, Shimoji T, Kuwahara N, Sakumura Y, Matsuishi K, Fujiwara Y, Motoshima T, Takahashi W, Yamada S, Kitada S, Fujimoto N, Nakayama T, Eto M, Takeya M. Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma. **Cancer Sci.** 107(5), 700-707, 2016.
6. Arakaki R, Yamasaki T, Kanno T, Shibasaki N, Sakamoto H, Utsunomiya N, Sumiyoshi T, Shibuya S, Tsuruyama T, Nakamura E, Ogawa O, Kamba T. CCL2 as a potential therapeutic target for clear cell renal cell carcinoma. **Cancer Med.** 5(10), 2920-2923, 2016
7. Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, Nakayama T, Kitada S, Kawano Y, Takahashi W, Sugimoto M, Takeya M, Fujimoto N, Oda Y, Eto M. PD-L1 expression in papillary renal cell carcinoma. **BMC Urol.** 17(1), 8, 2017
8. Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Masumori N, Egawa S, Sakai H, Okada Y, Terachi T, Ogawa O; ZAPCA Study Group. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. **Int J Clin Oncol.** 22(1), 166-173, 2017
9. Motoshima T, Miura Y, Wakagami N, Kusada N, Takano T, Inoshita N, Okaneya T, Sugiyama Y, Kamba T, Takeya M, Komohara Y; Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma. **Med Mol Morphol.** 51(1), 57-63, 2018
10. Asano T, Ohnishi K, Shiota T, Motoshima T, Sugiyama Y, Yatsuda J, Kamba T, Ishizaka K, Komohara Y; CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis. **Cancer Sci.** 2018 Mar 9. doi: 10.1111/cas.13565

【和文総説（原著論文、総説、著書など）】

1. 神波大己：ロボット時代の泌尿器科手術① 前立腺癌に対する新たなスタンダード。臨床泌尿器科, 69(10), 840-846, 2015
2. 田上憲一郎：手術（治療法）（テーマ 進行性がん）。泌尿器ケア 2015 年夏季増刊（MCメディカ出版），43-46, 2015
3. 榊田裕士、高橋渡、田上憲一郎、杉山豊、河野吉昭、江藤正俊。腹腔鏡下根治的前立腺全摘除術におけるトラブルシューティング。Japanese Journal of Endourology, 29, 20-23, 2016
4. 神波大己。ロボット手術におけるトラブルシューティング。Japanese Journal of Endourology, 29, 24-27, 2016
5. 神波大己。去勢抵抗性前立腺癌に対する治療の実際。日本臨牀増刊号 新前立腺癌学（日本臨牀社），632-639, 2016
6. 山口隆大、神波大己。進行直腸癌に対する泌尿器臓器合併切除（膀胱・精嚢・前立腺）。消化器外科, 40, 1533-1538, 2017
7. 神波大己。前立腺癌骨転移による骨関連事象とその予防。泌尿器外科, 30, 1511-1516, 2017
8. 村上洋嗣、神波大己。Topics of RCC～腎癌診療ガイドライン 2017 年版改定のポイント～。4. 術前・術後補助薬物療法。Year Book of RCC 2017（メディカルレビュー社），47-53, 2017
9. 神波大己。VIII. 腎癌の治療 3. 薬物療法 (3) サイトカイン療法。日本臨牀増刊号 新腎・泌尿器癌上（日本臨牀社），301-305, 2017

眼科学分野

【研究プロジェクト名および概要】

1. 緑内障手術の奏功メカニズムの解明と制御による新しい緑内障手術の開発に関する研究
2. 房水流出路の制御による新しい治療の創出に関する研究
3. 網膜・視神経の神経保護・再生治療の開発に関する研究
4. 房水に含まれる生理活性物質の解析と開放隅角緑内障の病態解明
5. 加齢黄斑変性の病態に関する基礎研究
6. 眼由来細胞における上皮間葉転換の病的意義に関する研究
7. Angiopoietin-like protein 2 の糖尿病網膜症の病態における機能解析
8. 家族性アミロイドポリニューロパシー眼合併症に関連する研究

【教職員および大学院学生】

【メールアドレス(任意)】

【研究プロジェクト】

教授

准教授

講師

診療講師

助教

大学院学生 (博士課程)

技術補佐員

事務補佐員

福島 美紀子

井上 俊洋

伊藤 康裕

高橋 枝里

芳賀 彰

藤本 智和

徳永 瞳

福島 亜矢子

二口 亜希子

川畑 和幸

松村 智世

江口 桃佳

渡辺 文香

舛本 悠

山村 小由里

3, 8

1, 2, 3, 4

7

3, 6

5

1, 2, 4

1, 4

5

1, 4

1

1, 4

1 ~ 8

研究の事務手続き

【連絡先】 電話: 096-373-5247 Fax: 096-373-5249

【ホームページ】 <http://www2.kuh.kumamoto-u.ac.jp/ganka/>

【特殊技術・特殊装置】

1. リアルタイム PCR 解析装置
2. 蛍光顕微鏡
3. ルミノメーター
4. ex vivo 房水流出量測定装置
5. 多極所網膜電図計測装置 (VERIS)
6. 超音波画像診断装置
7. 広角眼底カメラ
8. 網膜光干渉断層計: OCT (CIRRUS, HRA)
9. 前眼部三次元画像解析装置

【英文論文】

1. Matsumura R, Inoue T, Matsumura A, Tanihara H. Efficacy of ripasudil as a second-line medication in addition to a prostaglandin analog in patients with exfoliation glaucoma: A pilot study. **Clinical Drug Investigation**, 37: 535-539, 2017.
2. Futakuchi A, Inoue T, Fujimoto T, Kuroda U, Inoue-Mochita M, Takahashi E, Ohira S, Tanihara H. Molecular mechanisms underlying the filtration bleb-maintaining effects of suberoylanilide hydroxamic acid (SAHA). **Investigative Ophthalmology & Visual Science**, 58: 2421-2429, 2017.
3. Fujimoto T, Inoue T, Ohira S, Awai-Kasaoka N, Kameda T, Inoue-Mochita M, Tanihara H. Inhibition of Rho kinase induces antioxidative molecules and suppresses reactive oxidative species in trabecular meshwork cells. **Journal of Ophthalmology**, 7598140, 2017.
4. Araie M, Iwase A, Sugiyama K, Nakazawa T, Tomita G, Hangai M, Yanagi Y, Murata H, Tanihara H, Burgoyne CF, Chauhan BC. Determinants and characteristics of Bruch's membrane opening and Bruch's membrane opening-minimum rim width in a normal Japanese population. **Investigative Ophthalmology & Visual Science** 58: 4106-4113, 2017.
5. Watanabe-Kitamura F, Inoue T, Kojima S, Nakashima KI, Fukushima A, Tanihara H. Prospective 3D Investigation of Bleb Wall after Trabeculectomy Using Anterior-Segment OCT. **Journal of Ophthalmology** 8261364, 2017.
6. Inoue T, Tanihara H. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma. **Expert Opinion on Pharmacotherapy**, 18: 1669-1673, 2017.
7. Shoji N, Arakaki Y, Nakamoto K, Yamamoto T, Kuwayama Y; Collaborative Bleb-related Infection Incidence and Treatment Study Group. Efficacy of predetermined therapeutic measures against bleb-related infection in the Collaborative Bleb-related Infection Incidence and Treatment Study. **Acta Ophthalmologica**, in press.
8. Haga A, Kawaji T, Ideta R, Inomata Y, Tanihara H. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration. **Acta ophthalmologica**, in press.
9. Tsutsumi-Kuroda U, Inoue T, Futakuchi A, Shobayashi K, Takahashi E, Kojima S, Inoue-Mochita M, Fujimoto T, Tanihara H. Decreased MCP-1/CCR2 axis-mediated chemotactic effect of conjunctival fibroblasts after transdifferentiation into myofibroblasts. **Experimental Eye Research**, in press.
10. Nakashima KI, Iwao K, Inoue T, Haga A, Tsutsumi T, Mochita MI, Fujimoto T, Tanihara H. Stimulation of the adenosine A3 receptor, not the A1 or A2 receptors, promote neurite outgrowth of retinal ganglion cells. **Experimental Eye Research**, in press.
11. Iraha S, Tu HY, Yamasaki S, Kagawa T, Goto M, Takahashi R, Watanabe T, Sugita S, Yonemura S, Sunagawa GA, Matsuyama T, Fujii M, Kuwahara A, Kishino A, Koide N, Eiraku M, Tanihara H, Takahashi M, Mandai M. Establishment of immunodeficient retinal degeneration model mice and functional maturation of human ESC-derived retinal sheets after transplantation. **Stem Cell Reports**, in press.
12. Honjo M, Tanihara H. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma. **Japanese Journal of Ophthalmology**, in press.

歯科口腔外科学分野

【研究プロジェクト名および概要】

I. 臨床研究

- I-1 口腔扁平上皮癌患者に対する術前化学放射線療法についての研究
- I-2 口腔扁平上皮癌患者に対する術後補助化学療法についての研究
- I-3 口腔癌患者における放射線治療後のドライマウスについての研究
- I-4 口腔癌患者における化学放射線療法後の口腔粘膜炎についての研究
- I-5 口腔癌患者に対する免疫療法についての臨床的研究
- I-6 口腔癌患者の術後機能と機能回復についての研究
- I-7 歯周病と循環器疾患の関連性についての臨床的研究
- I-8 口腔フローラと全身疾患との関連性についての研究
- I-9 薬剤関連顎骨壊死に関する臨床的研究

II. 基礎研究

- II-1 口腔扁平上皮癌の転移機構についての研究
 - A-1 リンパ節転移機構の解明
 - A-2 遠隔転移機構の解明
 - A-3 エピジェネティクス制御による転移機構について
 - A-4 がん微小環境と転移機構について
- II-2 口腔扁平上皮癌の薬剤耐性についての研究
 - A-1 CDDP、5-FU、抗EGFR抗体に対する薬剤耐性機構について
 - A-2 エピジェネティクス制御による薬剤耐性機構について
 - A-3 がん微小環境と薬剤耐性機構について
- II-3 口腔扁平上皮癌の放射線耐性についての研究
 - A-1 低酸素状態と放射線耐性機構について
 - A-2 エピジェネティクス制御による放射線耐性機構について
 - A-3 がん微小環境と放射線耐性機構について
- II-4 口腔癌患者に対する免疫療法についての基礎的研究
ペプチドワクチン療法の効果の検討
- II-5 放射線照射と唾液腺細胞の機能についての研究
- II-6 歯周病と全身疾患の関連性についての基礎的研究

【研究者および大学院生】

教授	中山秀樹
准教授	吉田遼司
助教	尾木秀直
助教	福間大喜
助教	廣末晃之
特任助教	川原健太
医員	米田雅一
医員	中元雅史
医員	中村拓哉
医員	小島拓
医員	鶴田未季
医員	有田英生
医員	坂田純基

【メールアドレス】

hinakaya@kumamoto-u.ac.jp
ryoshida1126@gmail.com
ogihidenao@gmail.com
daikifukuma@gmail.com
ahiro711@gmail.com
k.k.ronbun@gmail.com
mameman1977@gmail.com
mabo.20jd.jm@gmail.com
takuyanamura2008@gmail.com
kutamajiko@gmail.com
miki.3one9@gmail.com
hidetaka.arita@gmail.com
j.sakata0510@gmail.com

【研究プロジェクト】

研究の統括
I-1~4, 6, 9 II-1~3, 5
I-1~4, 6, II-6
I-1, 2, 5, 6, II-4
I-1, 2, 8, II-1~3, 6
I-1, 2, 7, 9 II-1~3, 5
II-1, 2
II-1~3, 6
I-1~5, II-1
I-2, 5, II-2, 4
I-2, 5, II-2, 4
I-1~3, II-1~3
I-1~3, II-1~3

大学院生 (博士課程 4年)	平山真弓
大学院生 (博士課程 4年)	山本達郎
大学院生 (博士課程 3年)	前城学
大学院生 (博士課程 2年)	川口翔
大学院生 (博士課程 2年)	山名啓介
大学院生 (博士課程 2年)	永尾優果
大学院生 (博士課程 2年)	郷原俊輔
大学院生 (博士課程 2年)	八木田麻耶
大学院生 (博士課程 1年)	竹下尚志
大学院生 (博士課程 1年)	内藤久貴
大学院生 (博士課程 1年)	岩本明日香
大学院生 (博士課程 1年)	劉 隣

II-1
II-1~3
II-1, 2
II-1~3
II-1~3
II-2, 6
II-1~3
II-1, 2
II-1, 2, 3
II-1, 2
II-4
II-1, 2

【連絡先】 TEL:096-373-5288, FAX:096-373-5286

【ホームページ】 <http://www2.kuh.kumamoto-u.ac.jp/oralsurgery/>

【英文論文】

1. Murakami R, Nakayama H, Semba A, Hiraki A, Nagata M, Kawahara K, Shiraishi S, Hirai T, Uozumi H, Yamashita Y. Prognostic impact of the level of nodal involvement: A retrospective analysis of patients with advanced oral squamous cell carcinoma. **Br J Oral Maxillofac Surg.** 55(1):50-5, 2017
2. Yoshida R, Ito T, Hassan WA, Nakayama H. Notch1 in oral squamous cell carcinoma. **Histol Histopathol.** 32(4): 315-23, 2017
3. Takahashi N, Wei F, Watanabe S, Hirayama M, Ohuchi Y, Fujimura A, Kaitsuka T, Sawa T, Nakayama H, Akaike T, Tomizawa K. Reactive sulfur species regulate tRNA methylation and contribute to insulin secretion. **Nucleic Acids Res.** 45(1):435-45, 2017
4. Sakata J, Yoshida R, Matsuoka Y, Nagata M, Hirose A, Kawahara K, Nakamura T, Nakamoto M, Hirayama M, Takahashi N, Nakashima H, Arita H, Ogi, H, Hiraki A, Shinohara M, Nakayama H. Predictive value of the combination of SMAD4 expression and lymphocyte infiltration in malignant transformation of oral leukoplakia. **Cancer Med.** 6(4) :730-8, 2017
5. Nakamoto M, Ishihara K, Watanabe T, Hirose A, Hino S, Shinohara M, Nakayama H, Nakao M. The Glucocorticoid Receptor Regulates the ANGPTL4 Gene in a CTCF-Mediated Chromatin Context in Human Hepatic Cells. **PLoS One** 12(1):e0169225, 2017
6. Kawahara K, Hiraki A, Yoshida R, Arita H, Matsuoka Y, Yamashita T, Koga K, Nagata M, Hirose A, Fukuma D, Nakayama H. Salivary duct carcinoma treated with cetuximab-based targeted therapy: a case report **Mol Clin Oncol.** 6(6):886-92, 2017
7. Tsukamoto H, Fujieda K, Hirayama M, Ikeda T, Yuno A, Matsumura K, Fukuma D, Nakayama H, Senju S, Nishimura Y. Soluble IL-6R expressed by myeloid cells Th1 differentiation and drives tumor progression. **Cancer Res.** 7(9):2279-91, 2017
8. Murakami R, Semba A, Kawahara K, Matsuyama K, Hiraki A, Nagata M, Toya R, Yamashita Y, Oya N, Nakayama H. Concurrent chemoradiotherapy with S-1 in patients with stage III-IV oral squamous cell carcinoma: A retrospective analysis of nodal classification based on the neck node level. **Mol Clin Oncol.** 7(1):140-4, 2017
9. Arita H, Nagata M, Yoshida R, Matsuoka Y, Hirose A, Kawahara K, Sakata J, Nakashima H, Kojima T, Toya R, Murakami R, Hiraki A, Shinohara M, Nakayama H. FBWX7 expression affects the response to chemoradiotherapy and overall survival among patients with oral squamous cell carcinoma: a retrospective study **Tumor Biol.** 39(10):1010428317731771, 2017
10. Koga K, Yoshida R, Nakamura T, Matsuoka Y, Takeshita H, Takahashi N, Nakamoto M, Hiraki A, Shinohara M, Nakayama H. A rare case of metachronous multiple supernumerary teeth in the bilateral premolar region of the mandible. **Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology** 29(2):132-5, 2017
11. Tsuruta M, Ueda S, Yew PY, Fukuda I, Yoshimura S, Kishi H, Hamana H, Yatsuda J, Irie A, Senjyu S, Yuba E, Kamba T, Eto M, Nakayama H, and Nishimura Y. Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro. **OncoImmunology** published online on Jan. 5, 2018
12. Sakata J, Yamana K, Yoshida R, Matsuoka Y, Kawahara K, Arita H, Nakashima H, Nagata M, Hirose A, Kawaguchi S, Gohara S, Nagao Y, Hiraki A, Shinohara M, Toya R, Murakami R, Nakayama H. Tumor budding as a novel predictor of occult metastasis in cT2N0 tongue squamous cell carcinoma. **Hum Pathol.** published online on Jan. 4, 2018
13. Shinriki S, Jono H, Maeshiro M, Nakamura T, Guo J, Li JD, Ueda M, Yoshida R, Shinohara M, Nakayama H, Matsui H, Ando Y. Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma. **J Pathol.** 244(3):367-79, 2018
14. Sakata S, Matsuoka Y, Kawahara K, Kakiuchi Y, Takaki A, Hirose A, Yoshida R, Saeki S, Fujii K, Nakayama H. Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis. **Respiratory Investigation** 56(2):195-8, 2018
15. Nagata, M, Kusafuka K, Yoshida R, Kawahara K, Nakagawa Y, Nakamoto M, Shinohara M, Nakayama H. Mucinous adenocarcinoma with signet ring cell features of the sublingual gland: A case report with an immunohistochemical analysis **Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology** published online on Feb. 3, 2018

皮膚病態治療再建学分野

【研究プロジェクト名および概要】

- I. 膠原病および水疱症、脱毛症における各種サイトカインおよび細胞外マトリックスの病態への関与
- II. 膠原病および皮膚悪性腫瘍における microRNA によるエピジェネティックな病態への関与
- III. 膠原病および炎症性皮膚疾患におけるプロテオーム解析
- IV. 培養線維芽細胞のサイトカイン応答およびシグナル伝達の研究
- V. 悪性黒色腫における新規腫瘍関連抗原の探索
- VI. 悪性黒色腫に対するイムノチェックポイント阻害剤のバイオマーカー探索
- VII. iPS 細胞由来の遺伝子改変マクロファージおよび樹状細胞による免疫療法の開発
- VIII. 皮膚疾患における HSV1, 2, 6, 7, VZV, EBV の関与
- IX. 乾癬表皮における蛋白発現、ケモカインの解析
- X. 皮膚悪性腫瘍におけるセンチネルリンパ節同定の研究
- X I. 皮膚末梢血管分布の解析
- X II. 皮膚血管腫、血管肉腫の遺伝子発現解析と病態解明
- X III. 皮膚老化と血管新生、コラーゲン蛋白の代謝機構の解明
- X IV. 細胞の表皮細胞、血管内皮細胞、線維芽細胞への分化誘導
- X V. 低酸素環境における血管肉腫悪性化機序の解明
- X VI. 難治性皮膚潰瘍および重症下肢虚血に対する末梢血単核球移植療法の開発

【教職員および大学院学生】

【メールアドレス(任意)】

【研究プロジェクト】

		研究の統括
教授	尹 浩信	II, V, VI, VII
准教授	福島 聡	V, X, XI
講師	増口信一	I, II, IV
講師	牧野貴充	V, X, XI
助教	伊方敏勝	II, X, XI
助教	青井 淳	IX, X II, X IV, X V
助教	梶原一亨	II, V, VI, VII
特任助教	宮下 梓(総合臨床研究部)	I, II, III, IV
特任助教	牧野雄成(免疫・アレルギー・血管病態学寄附講座)	II, V, VI, VII
特任助教	徳澄亜紀(専門医療実践学寄附講座)	I, II, III, IV
診療助手	本多教稔(形成再建科)	I, II, III, IV
診療助手	中山若菜(褥瘡対策室長)	IX
診療助手	谷川大紀(集中治療部)	I, II, III
診療助手	田中憲一郎(集中治療部)	I, II, III
医員	中原智史、金澤早織、門久美菜、金丸央、渡邊千夏、島田佳奈子、水谷 望、小林温子、丸田志野、永野美和、福岡聖菜、松下晴香、江川清文、井上久仁子、山内 恵、永元英子	
大学院学生(博士課程)	押川由佳	I, II, IV
大学院学生(博士課程)	清原美穂子	II, X, XI
大学院学生(博士課程)	澤村創一郎	I, II, III, IV
大学院学生(博士課程)	中島聡子	I, II, III, IV
大学院学生(博士課程)	坂元亮子	IX, X II, X IV, X V
大学院学生(修士課程)	島田秀一	I, II, III, IV
大学院学生(修士課程)	大塚紗希	IX, X II, X IV, X V
大学院学生(修士課程)	栗山春香	IX, X II, X IV, X V
大学院学生(修士課程)	川野勇歩	I, II, III, IV
大学院学生(修士課程)	木村俊寛	IX, X II, X IV, X V
大学院学生(修士課程)	山下智香	I, II, III, IV
大学院学生(修士課程)	石橋卓行	IX, X II, X IV, X V
大学院学生(修士課程)	林 みゆき	I, II, III, IV

【連絡先】 電話： 096-373-5233 Fax： 096-373-5235

【ホームページ】 http://www2.kuh.kumamoto-u.ac.jp/derm_plas/

【特殊技術・特殊装置】

1. 凍結マイクロトーム LEICA CM3050S
2. 蛍光顕微鏡カールツアイツ 80DM
3. JMEC 社製 Q スイッチルビレーザ
4. Candela 社製 Vbeam[®]色素レーザー
5. Qubit フルオロメーター(サーモフィッシャー)
6. Microplate reader (サーモフィッシャー MultiskanFC)
7. Bio clean bench (SANYO)
8. CO2 incubator (SANYO)
9. Thermal Cycler Dice[™] Real Time System (TAKARA)
10. ChemiDoc XRS (BIO-RAD)
11. NanoDrop Lite (Eppendorf)
12. Dynamic RI シンチグラフィ

【英文論文】

1. Luong VH, Chino T, Oyama N, Matsushita T, Sasaki Y, Ogura D, Niwa SI, Biswas T, Hamasaki A, Fujita M, Okamoto Y, Otsuka M, Ihn H, Hasegawa M. Blockade of TGF- β /Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis. **Arthritis Res Ther.** 2018 Mar 15;20(1):46. (IF 4.121)
2. Sawamura S, Jinnin M, Inoue K, Yamane K, Honda N, Kajihara I, Makino T, Masuguchi S, Fukushima S, Ihn H. Regulatory mechanisms of collagen expression by interleukin-22 signaling in scleroderma fibroblasts. **J Dermatol Sci.** 2018 Apr;90(1):52-59. (IF3.773)
3. Yamamoto Y, Makino T, Kudo H, Ihn H, Murakami Y, Matsufuji S, Fujiwara K, Shin M. Expression and distribution patterns of spermine, spermidine, and putrescine in rat hair follicle. **Histochem Cell Biol.** 2018 Feb;149(2):161-167. (IF2.553)
4. Egashira S, Jinnin M, Ajino M, Shimozono N, Okamoto S, Tasaki Y, Hirano A, Ide M, Kajihara I, Aoi J, Harada M, Igata T, Masuguchi S, Fukushima S, Ihn H. Chronic sun exposure-related fusion oncogenes EGFR-PPARGC1A in cutaneous squamous cell carcinoma. **Sci Rep.** 2017 Oct 4;7(1):12654. (IF 4.259)
5. Ogata-Aoki H, Higashi-Kuwata N, Hattori SI, Hayashi H, Danish M, Aoki M, Shiotsu C, Hashiguchi Y, Hamada A, Kobayashi H, Ihn H, Okada S, Mitsuya H. Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1JR-FL in the setting of post-exposure prophylaxis in NOD/SCID/Jak3^{-/-} mice transplanted with human PBMCs. **Antiviral Res.** 2018 Jan;149:78-88. (IF4.271)
6. Inoue M, Miyashita A, Noguchi H, Hirose N, Nishimura K, Masuda M, Ihn H. Case report of cutaneous protothecosis caused by Prototheca wickerhamii designated as genotype 2 and current status of human protothecosis in Japan. **J Dermatol.** 2018 Jan;45(1):67-71. (IF 2.094)
7. Kajihara I, Yamada-Kanazawa S, Maeda-Otsuka S, Jinnin M, Akaike K, Ihn H. Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris. **J Dermatol.** 2017 Dec;44(12):e322-e323. (IF 2.094)
8. Nakashima S, Jinnin M, Kanemaru H, Kajihara I, Igata T, Okamoto S, Tazaki Y, Harada M, Masuguchi S, Fukushima S, Masuzawa M, Amoh Y, Masuzawa M, Ihn H. The role of miR-210, E2F3 and ephrin A3 in angiosarcoma cell proliferation. **Eur J Dermatol.** 2017 Oct 1;27(5):464-471. (IF2.247)
9. Abe M, Nishigori C, Torii H, Ihn H, Ito K, Nagaoka M, Isogawa N, Kawaguchi I, Tomochika Y, Kobayashi M, Tallman AM, Papp KA. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial. **J Dermatol.** 2017 Nov;44(11):1228-1237. (IF 2.094)
10. Sato Y, Kajihara I, Yamada-Kanazawa S, Jinnin M, Ihn H. S100A7 expression levels in coordination with interleukin-8 indicate the clinical response to infliximab for psoriasis patients. **J Dermatol.** 2017 Jul;44(7):838-839. (IF 2.094)
11. Nakamura Y, Kajihara I, Yamada-Kanazawa S, Maeda-Otsuka S, Johno T, Aoi J, Igata T, Masuguchi S, Fukushima S, Jinnin M, Ihn H. Intratumor dihydropyrimidine dehydrogenase mRNA expression levels are decreased in extramammary Paget's disease. **Drug Discov Ther.** 2017 Jul 31;11(3):152-155. (IF 1.47)
12. Oka A, Asano Y, Hasegawa M, Fujimoto M, Ishikawa O, Kuwana M, Kawaguchi Y, Yamamoto T, Takahashi H, Goto D, Endo H, Jinnin M, Mano S, Hosomichi K, Mabuchi T, Ueda MT, Nakagawa S, Beck S, Bahram S, Takehara K, Sato S, Ihn H. RXRB Is an MHC-Encoded Susceptibility Gene Associated with Anti-Topoisomerase I Antibody-Positive Systemic Sclerosis. **J Invest Dermatol.** 2017 Sep;137(9):1878-1886. (IF 6.287)
13. Ichihara A, Jinnin M, Ihn H. Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis. **Clin Exp Rheumatol.** 2017 Sep-Oct;35 Suppl 106(4):208-210. (IF 1.16)
14. Ide M, Jinnin M, Tomizawa Y, Wang Z, Kajihara I, Fukushima S, Hashizume Y, Asano Y, Ihn H. Transforming growth factor β -inhibitor Repsox downregulates collagen expression of scleroderma dermal fibroblasts and prevents bleomycin-induced mice skin fibrosis. **Exp Dermatol.** 2017 Nov;26(11):1139-1143. (IF2.532)
15. Higashi-Kuwata N, Ogata-Aoki H, Hattori SI, Hayashi H, Danish M, Aoki M, Shiotsu C, Kawamura T, Ihn H, Kobayashi H, Okada S, Mitsuya H. Early phase dynamics of traceable mCherry fluorescent protein-carrying HIV-1 infection in human peripheral blood mononuclear cells-transplanted NOD/SCID/Jak3^{-/-} mice. **Antiviral Res.** 2017 Aug;144:83-92. (IF4.271)
16. Sawamura S, Jinnin M, Shimbara M, Nakamura K, Kudo H, Inoue K, Nakayama W, Kajihara I, Fukushima S, Ihn H. Serum levels of genomic DNA of $\alpha 1(I)$ collagen are elevated in scleroderma patients. **J Dermatol.** 2017 Aug;44(8):927-931. (IF 2.094)

17. Sawamura S, Kajihara I, Jinnin M, Honda Y, Ihn H. Cutaneous spindle cell adenolipoma on the nose: A rare variant of lipoma. **J Dermatol.** 2017 Jul;44(7):e156-e157. (IF 2.094)
18. Yamazaki N, Kiyohara Y, Uhara H, Uehara J, Fujimoto M, Takenouchi T, Otsuka M, Uchi H, Ihn H, Minami H. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. **Cancer Sci.** 2017 Jun;108(6):1223-1230. (IF3.974)
19. Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, Kawaguchi Y, Matucci-Cerinic M, Ohmura K, Riemekasten G, Kawasaki A, Airo P, Horita T, Oka A, Hachulla E, Yoshifuji H, Caramaschi P, Hunzelmann N, Baron M, Atsumi T, Hassoun P, Torii T, Takahashi M, Tabara Y, Shimizu M, Tochimoto A, Ayuzawa N, Yanagida H, Furukawa H, Tohma S, Hasegawa M, Fujimoto M, Ishikawa O, Yamamoto T, Goto D, Asano Y, Jinnin M, Endo H, Takahashi H, Takehara K, Sato S, Ihn H, Raychaudhuri S, Liao K, Gregersen P, Tsuchiya N, Riccieri V, Melchers I, Valentini G, Cauvet A, Martinez M, Mimori T, Matsuda F, Allanore Y. Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. **Ann Rheum Dis.** 2017 Jun;76(6):1150-1158. (IF12.811)
20. Noguchi H, Hiruma M, Matsumoto T, Yaguchi T, Tashima H, Ihn H. Multiple subcutaneous Candida abscesses on the palm and finger in an immunocompetent patient. **J Dermatol.** 2017 Jul;44(7):e176-e177. (IF 2.094)
21. Noguchi H, Hiruma M, Matsumoto T, Kano R, Tanaka M, Yaguchi T, Sonoda K, Ihn H. Fungal Melanonychia: Ungual Phaeohiphomyces caused by Botryosphaeria dothidea. **Acta Derm Venereol.** 2017 Jun 9;97(6):765-766. (IF3.653)
22. Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Wada H, Noguchi K, Shimamoto T, Yokota K. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). **Cancer Chemother Pharmacol.** 2017 Apr;79(4):651-660. (IF2.737)
23. Yamazaki N, Kiyohara Y, Uhara H, Iizuka H, Uehara J, Otsuka F, Fujisawa Y, Takenouchi T, Isei T, Iwatsuki K, Uchi H, Ihn H, Minami H, Tahara H. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. **Cancer Sci.** 2017 May;108(5):1022-1031. (IF3.974)
24. Noguchi H, Hiruma M, Matsumoto T, Yaguchi T, Sano A, Mitsui N, Watanabe S, Ihn H. Subcutaneous cystic phaeohiphomyces due to Pleurostomophora richardsiae. **J Dermatol.** 2017 Apr;44(4):e62-e63. (IF 2.094)
25. Torii H, Nakano M, Yano T, Kondo K, Nakagawa H; SPREAD Study Group. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study. **J Dermatol.** 2017 May;44(5):552-559. (IF 2.094)
26. Egashira S, Kajihara I, Kanemaru H, Uemura-Kiyohara M, Yamada-Kanazawa S, Nakahara S, Nagamoto E, Fukushima S, Jinnin M, Inoue Y, Ihn H. Achieved good response of S-1 and docetaxel combination chemotherapy in two patients with metastatic extramammary Paget's disease. **J Dermatol.** 2017 May;44(5):e103-e104. (IF 2.094)
27. Maeda S, Kajihara I, Ogata A, John T, Jinnin M, Ihn H. Bromoderma in a pituitary adenoma patient treated with bromocriptine. **J Dermatol.** 2017 May;44(5):e95-e96. (IF 2.094)
28. Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO; Japanese Ixekizumab Study Group. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). **J Dermatol.** 2017 Apr;44(4):355-362. (IF 2.094)
29. Noguchi H, Hiruma M, Matsumoto T, Kano R, Ihn H. Ungual aspergillosis successfully treated with topical efinaconazole. **J Dermatol.** 2017 Jul;44(7):848-850. (IF 2.094)
30. Sawamura S, Kajihara I, Makino K, Makino T, Fukushima S, Jinnin M, Oyama B, Hashimoto T, Ihn H. Systemic lupus erythematosus associated with myasthenia gravis, pemphigus foliaceus and chronic thyroiditis after thymectomy. **Australas J Dermatol.** 2017 Aug;58(3):e120-e122. (IF1.304)
31. Amagai M, Ikeda S, Hashimoto T, Mizuashi M, Fujisawa A, Ihn H, Matsuzaki Y, Ohtsuka M, Fujiwara H, Furuta J, Tago O, Yamagami J, Tanikawa A, Uhara H, Morita A, Nakanishi G, Tani M, Aoyama Y, Makino E, Muto M, Manabe M, Konno T, Murata S, Izaki S, Watanabe H, Yamaguchi Y, Matsukura S, Seishima M, Habe K, Yoshida Y, Kaneko S, Shindo H, Nakajima K, Kanekura T, Takahashi K, Kitajima Y, Hashimoto K. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. **J Dermatol Sci.** 2017 Feb;85(2):77-84. (IF3.773)
32. Noguchi H, Hiruma M, Matsumoto T, Kano R, Ihn H. Ungual hyalohyphomycosis caused by Fusarium proliferatum in an immunocompetent patient. **J Dermatol.** 44: 88-90, 2017. (IF 2.094)
33. Satoshi Nakahara, Satoshi Fukushima, Junji Yamashita, Yosuke Kubo, Aki Tokuzumi, Azusa Miyashita, Miho Harada, Kayo Nakamura, Masatoshi Jinnin, Hironobu Ihn. AT-rich Interaction Domain-containing Protein 3B is a New Tumour Marker for Melanoma. **Acta Derm Venereol.** 2017 Jan 4;97(1):112-114. (IF3.653)
34. Hamaguchi Y, Sumida T, Kawaguchi Y, Ihn H, Tanaka S, Asano Y, Motegi S, Kuwana M, Endo H, Takehara K. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study. **J Dermatol.** 2017 Jan;44(1):13-17. (IF 2.094)
35. Nakayama W, Jinnin M, Tomizawa Y, Nakamura K, Kudo H, Inoue K, Makino K, Honda N, Kajihara I, Fukushima S, Ihn H. Dysregulated interleukin-23 signalling contributes to the increased collagen production in scleroderma fibroblasts via balancing microRNA expression. **Rheumatology (Oxford).** 2017 Jan;56(1):145-155. (IF 4.818)
36. Harada M, Jinnin M, Wang Z, Hirano A, Tomizawa Y, Kira T, Igata T, Masuguchi S, Fukushima S, Ihn H. The expression of miR-124 increases in aged skin to cause cell senescence and it decreases in squamous cell carcinoma. **Biosci Trends,** 2017 Jan 16;10(6):454-459. (IF 1.545)

37. Wang Z, Jinnin M, Harada M, Kudo H, Inoue K, Nakayama W, Honda N, Makino K, Kajihara I, Fukushima S, Ihn H. Diagnosis of nail psoriasis: evaluation of nail-derived microRNAs as potential novel biomarkers. **Eur J Dermatol.** 2017 Feb 1;27(1):20-27. (IF2.247)
38. Yamada-Kanazawa S, Kajihara I, Fukushima S, Jinnin M, Masuzawa M, Masuzawa M, Amoh Y, Hoshina D, Abe R, Ihn H. Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway. **Br J Dermatol.** 2017 Aug;177(2):456-469. (IF 4.706)
39. Weber J, Mandala M, Del Vecchio M, Ggas HJ, Arance AM, Cowey CL, Dalle S, Svhenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, LeBBe C, Rutkowski P, Yokota K, Yamazaki N, Kin TM, de Prol V, Sabater J, Qureshi A, Larkin J, Ascerto PA, Cinat G, Zarba J, Brown M, Carlino M, Cebon J, Haydon A, Hersey P, Hill A, McNeil C, Millward M, Laimer M, Richtig E, Bauriain JF, Beuselinck B, Kruse V, Neyns B, Claveau J, Miller W, Savage K, Arenberger P, Krajsova I, Kubala E, Vantuchova Y, Hernberg M, Skyttä T, Dreno B, Bafaloukos D, Liskay G, Donnellan P, Gullo G, McCaffrey J, Cognetti F, Guidoboni M, Queirolo P, Fujimoto M, Ihn H, Inozume T, Koga H, Ozawa K, Takenouchi T, Uchi H, Yoshikawa S, Lee DH, Lee J, Shin SJ, Hospers G, Koornstra R, Van Den Eertwegh A, Vreugdenhil G, Nyakas M, Straume O, Pikiel J, Ziobro M, Ciuleanu T, Cohen G, Jacobs C, McAdam G, Rapoport BL, Vorobiof D, Berrocal A, De La Cruz L, Carneiro A, Ny L, Dummer R, Chen YY, Lin CY, Faust G, Herbert C, Lorigan P, Nathan P, Ottensmeier C, Plummer R, Wagstaff J, Agarwala S, Amatruda T, Amin A, Curti B, Daniels G, Daud A, Fecher L, Gaughan E, Hamid O, Hernandez Aya L, Hutchins L, Infante J, Kendra K, Khushalani N, Kim K, Luke J, Lutzky J, Nair S, Ott PA, Pavlick A, Pecora A, Reuben D, Salama A, Shoushtari A, Silk A, Taylor M, Thomas S, Zaiden R. Ajuvant nivolumab versus ipillimumab in resected stage III or IV melanoma. **N Engl J Med.** 2017 Nov 9;377(19):1824-1835.. (IF 72.406)
40. Aoi J, Fukushima S, Jinnin M, Ihn H. Fluorescence in situ hybridization for diagnosis of malignant melanoma using RREB1, MYB, Cep6, and CCND1 probes in Japanese patients. **Dermatologica Sinica**, 35: 213-214, 2017. (IF 0.540)
41. Ishibashi T, Jinnin M, Kajihara I, Fukushima S, Ihn H. Bullous dermatosis of the elderly leg: a new clinical entity? **Drug Discov Ther.** 2017;11(6):346-348.(IF 1.47)
42. Sawamura S, Jinnin M, Inoue K, Yamane K, Honda N, Kajihara I, Makino T, Masuguchi S, Fukushima S, Ihn H. Regulatory mechanisms of collagen expression by interleukin-22 signaling in scleroderma fibroblasts. **J Dermatol Sci.** 2018 Apr;90(1):52-59. (IF3.773)
43. Umezaki N, Ishimoto T, Koba I, Nakaya T, Mawatari M, Kuramoto K, Izumi D, Sakamoto Y, Miyamoto Y, Yoshida N, Watanabe M, Inoue Y, Ihn H, Baba H. Anorectal malignant melanoma with extensive intraepithelial extension: report of a case. **Int Canc Conf J**, in press
44. Noda-Yamashita T, Kajihara I, Kidou M, Ihn H. Dyskeratosis congenital associated with congenital hypothyroidism. **J Dermatol.** 2017 Oct 23. [Epub ahead of print] (IF 2.094)
45. Kanamori S, Kajihara I, Kanazawa-Yamada S, Otsuka-Maeda S, Ihn H. Expression of aurora kinase A in dermatofibrosarcoma protuberans. **J Dermatol**, in press. (IF 2.094)
46. Okiyama N, Asano Y, Hamaguchi Y, Jinnin M, Motegi SI, Koizumi H, Hasegawa M, Ishikawa O, Sato S, Takehara K, Yamamoto T, Fujimoto M, Ihn H. Impact of a new simplified disability scoring system for adult patients with localized scleroderma. **J Dermatol.** 45: 431-435, 2018 (IF 2.094)
47. Shimada S, Fukushima S, Niimori D, Miyashita A, Setoyama H, Sasaki Y, Ihn H. Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib. **J Dermatol.** 2018 Jan 6. [Epub ahead of print] (IF 2.094)
48. Ikeda I, Igata T, Ihn H. First Aid for Skin Tears by Mini Patch Grafting from the Flap Edge. **J Emerg Med.** 2018 Jan 3. pii: S0736-4679(17)31183-6. [Epub ahead of print] (IF1.210)
49. Hasegawa M, Ishikawa O, Asano Y, Sato S, Jinnin M, Takehara K, Fujimoto M, Yamamoto T, Ihn H; Executive Committee of Guideline. Diagnostic criteria, severity classification and guideline of lichen sclerosus et atrophicus. **J Dermatol.** 2017 Dec 19. [Epub ahead of print] (IF 2.094)
50. Jinnin M, Yamamoto T, Asano Y, Ishikawa O, Sato S, Takehara K, Hasegawa M, Fujimoto M, Ihn H. Guideline for diagnostic criteria, severity classification and treatment of eosinophilic fasciitis. **J Dermatol.** 2017 Dec 13. [Epub ahead of print] (IF 2.094)
51. Sonoda-Shimada K, Kajihara I, Shimada S, Igata T, Jinnin M, Honda Y, Ihn H. Case of pigmented lipofibromatosis in a 27-year-old woman. **J Dermatol.** 2017 Nov 27. [Epub ahead of print] (IF 2.094)
52. Noda-Yamashita T, Kajihara I, Kidou M, Ihn H. Dyskeratosis congenita associated with congenital hypothyroidism. **J Dermatol.** 2017 Oct 23. [Epub ahead of print] (IF 2.094)

臨床国際協力学分野

(国立病院機構熊本医療センター・大学院連携講座)

【研究プロジェクト名および概要】

I. 救急搬送患者の在院死亡率予測法の開発

救急外来に搬送されてくる患者の多くは重症であり、救命病棟やICU等での入院管理を要することが多い。しかし、その一方で、軽症であり、入院を要しない患者も混在している。救急外来で、これら患者の重症度を簡便に見分ける方法はなく、これらの患者の入院振り分けや重症度の判定は担当医の勘に頼っているのが現状である。本研究の目的は、救急車のプレホスピタルレコードを用いて患者のバイタルサインや意識状態から、救急搬送患者の予後を予測する方法を開発することにある。

II. 敗血症性播種性血管内凝固症における予後予測因子としての Protein C 活性の検討

重症感染症では高率に播種性血管内凝固(Disseminated intravascular coagulation, DIC)を合併し、その予後は不良である。重症感染症患者の予後予測因子としては APACHE II スコアが開発されているが、スコア算出は煩雑であり、より簡便な予測因子が望まれる。近年、Antithrombin (AT)値が重症感染症において有意に低下し、生命予後の予測因子になることは広く知られるようになり、APACHEII スコアの代替指標となり得ることが期待されている。我々は、感染性 DIC では Protein C (PC)値も AT 値同様に低下することに着目した。本研究では、感染性 DIC 患者において PC 値が予後予測因子となり得るか検討する。

III. 救急外来における向精神薬大量服薬患者の予後予測因子の検討

救急外来には、向精神薬の大量服薬患者が多数搬送されてくる。これらの患者の多くは年齢が若く、軽症であり、入院を要しないことが多いが、中には誤嚥性肺炎や薬物中毒症状を呈し、ICU等で入院管理を要することもある。救急外来で、これら患者の重症度を簡便に見分ける方法はなく、これらの患者の入院振り分けは担当医の勘に頼っているのが現状である。本研究の目的は、救急車のプレホスピタルレコードを用いて患者のバイタルサインや意識状態から、大量向精神薬服薬患者の予後を予測する方法を開発することにある。

IV. 心停止蘇生後のストレス反応・炎症反応・血糖値の検討

心停止後蘇生患者で、蘇生直後のストレス反応マーカー及び血糖値と生命予後の関係を調査し、予後因子を明らかにする。

V. 妊娠糖尿病の病態解析

妊娠糖尿病はたとえ糖尿病の程度が軽度であっても巨大児など、周産期の様々な合併症のリスクとなる。また一方、妊娠糖尿病と診断された女性は将来の2型糖尿病発症のハイリスク群でもある。本研究では、妊娠糖尿病診断の時点でインスリン治療の必要性および将来の2型糖尿病発症について、予測が可能であるか検討する。

VI. 抗 GAD 抗体陽性妊娠糖尿病患者のフォローアップ研究

妊娠糖尿病患者の6.2%(24/385例)で抗GAD抗体などの膵島関連自己抗体が陽性であること、その中の50%(12例)で1型糖尿病が発症したこと、またその発症時期は5年以内が91.6%であったことが海外から報告された。抗GAD抗体陽性妊娠糖尿病患者は1型糖尿病発症の高リスク群と考えられるが、本邦における同様の報告は見当たらない。本研究は、抗GAD抗体陽性妊娠糖尿病患者の1型糖尿病発症率および糖代謝病態の変化を調査する目的とした、当科受診歴のある妊娠糖尿病患者を対象とした前向き観察研究である。

【教職員および大学院学生】	【メールアドレス】	【研究プロジェクト】	
教授（客員）	西川 武志	t-nishikawa@kumamed.jp	研究統括, V, VI
准教授（客員）	高橋 毅	t99@kumamed.jp	I, II, III, IV
大学院学生（博士課程）	原田 正公		I
大学院学生（博士課程）	櫻井 聖大		II
大学院学生（博士課程）	北田 真己		III
大学院学生（博士課程）	山田 周		IV

【連絡先】 Tel: 096-353-6501 Fax: 096-325-2519

【ホームページ】 <http://www.nho-kumamoto.jp/medical/kumamotouniversity.html>

【英文論文】

1. Kukidome D, Nishikawa T, Sato M, Nishi Y, Shimamura R, Kawashima J, Shimoda S, Mizuta H, Araki E. Impaired balance is related to the progression of diabetic complications in both young and older adults. J Diabetes Complications. 2017;31(8):1275-82.
2. Kajihara N, Kukidome D, Sada K, Motoshima H, Furukawa N, Matsumura T, Nishikawa T, Araki E. Low glucose induces mitochondrial reactive oxygen species via fatty acid oxidation in bovine aortic endothelial cells. Journal of diabetes investigation. 2017;8(6):750-61.
3. Araki E, Haneda M, Kasuga M, Nishikawa T, Kondo T, Ueki K, Kadowaki T. New glycemic targets for patients with diabetes from the Japan Diabetes Society. Journal of diabetes investigation. 2017;8(1):123-5.